Table 2: Updated MIPS Benchmark Results Using DY2016 and PY2018 Logic,,,,,,,,,,,,,
,,,,,,,,,,,,,
Measure_Name,Measure_ID,Submission_Method,Measure_Type,Benchmark,Decile 3,Decile 4,Decile 5,Decile 6,Decile 7,Decile 8,Decile 9,Decile 10,Topped Out
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Claims, Intermediate Outcome,Y,33.33 - 23.54,23.53 - 18.25,18.24 - 14.30,14.29 - 11.55,11.54 -  8.90,8.89 -  6.26,6.25 -  3.34,<=  3.33,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,EHR, Intermediate Outcome,Y,83.10 - 67.96,67.95 - 54.09,54.08 - 43.22,43.21 - 34.12,34.11 - 27.28,27.27 - 21.75,21.74 - 15.74,<= 15.73,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Registry/QCDR, Intermediate Outcome,Y,57.89 - 42.37,42.36 - 31.59,31.58 - 25.78,25.77 - 20.94,20.93 - 16.82,16.81 - 12.78,12.77 -  7.70,<=  7.69,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,EHR,Process,Y,43.53 - 53.26,53.27 - 62.85,62.86 - 68.74,68.75 - 72.40,72.41 - 77.91,77.92 - 85.18,85.19 - 91.33,>= 91.34,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,Registry/QCDR,Process,Y,79.25 - 82.92,82.93 - 85.52,85.53 - 88.88,88.89 - 91.66,91.67 - 94.43,94.44 - 96.76,96.77 - 99.99,100,No
Coronary Artery Disease (CAD): Antiplatelet Therapy,6,Registry/QCDR,Process,Y,81.22 - 84.94,84.95 - 87.49,87.50 - 89.56,89.57 - 91.61,91.62 - 93.34,93.35 - 95.80,95.81 - 99.99,100,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%),7,EHR,Process,Y,51.35 - 68.22,68.23 - 78.77,78.78 - 82.64,82.65 - 86.32,86.33 - 90.79,90.80 - 94.25,94.26 - 97.60,>= 97.61,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%),7,Registry/QCDR,Process,Y,72.55 - 79.06,79.07 - 84.43,84.44 - 88.51,88.52 - 91.17,91.18 - 94.28,94.29 - 98.03,98.04 - 99.99,100,No
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,EHR,Process,Y,60.00 - 65.78,65.79 - 70.58,70.59 - 74.99,75.00 - 79.99,80.00 - 85.95,85.96 - 90.47,90.48 - 95.99,>= 96.00,No
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,Registry/QCDR,Process,Y,83.83 - 87.49,87.50 - 90.62,90.63 - 93.09,93.10 - 95.44,95.45 - 97.13,97.14 - 99.99,--,100,No
Anti-Depressant Medication Management,9,EHR,Process,Y,54.90 - 69.89,69.90 - 80.35,80.36 - 85.86,85.87 - 88.56,88.57 - 90.71,90.72 - 92.96,92.97 - 96.53,>= 96.54,No
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Claims,Process,Y,98.99 - 99.99,--,--,--,--,--,--,100,Yes
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,EHR,Process,Y,82.75 - 87.40,87.41 - 90.76,90.77 - 93.62,93.63 - 96.16,96.17 - 97.87,97.88 - 98.96,98.97 - 99.99,100,No
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Registry/QCDR,Process,Y,94.70 - 98.14,98.15 - 99.16,99.17 - 99.99,--,--,--,--,100,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Claims,Process,Y,99.60 - 99.99,--,--,--,--,--,--,100,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Registry/QCDR,Process,Y,64.21 - 81.81,81.82 - 90.85,90.86 - 95.69,95.70 - 98.64,98.65 - 99.99,--,--,100,Yes
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy,18,EHR,Process,Y,57.14 - 65.83,65.84 - 72.72,72.73 - 78.21,78.22 - 83.12,83.13 - 88.17,88.18 - 92.30,92.31 - 96.32,>= 96.33,No
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,EHR,Process,Y,46.15 - 56.85,56.86 - 65.13,65.14 - 72.38,72.39 - 78.21,78.22 - 84.27,84.28 - 89.93,89.94 - 95.41,>= 95.42,No
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Registry/QCDR,Process,Y,52.00 - 72.40,72.41 - 81.47,81.48 - 90.76,90.77 - 96.54,96.55 - 99.99,--,--,100,No
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Claims,Process,Y,99.13 - 99.99,--,--,--,--,--,--,100,Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Registry/QCDR,Process,Y,98.09 - 99.99,--,--,--,--,--,--,100,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Registry/QCDR,Process,Y,95.49 - 99.72,99.73 - 99.99,--,--,--,--,--,100,Yes
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,Claims,Process,Y,78.43 - 90.90,90.91 - 94.28,94.29 - 96.29,96.30 - 97.66,97.67 - 99.99,--,--,100,Yes
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,Registry/QCDR,Process,Y,9.29 - 18.57,18.58 - 28.56,28.57 - 36.05,36.06 - 60.92,60.93 - 86.66,86.67 - 99.99,--,100,No
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,Claims,Process,Y,29.30 - 38.45,38.46 - 45.60,45.61 - 52.33,52.34 - 60.39,60.40 - 69.94,69.95 - 81.57,81.58 - 95.67,>= 95.68,No
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,Registry/QCDR,Process,Y,13.36 - 29.05,29.06 - 47.01,47.02 - 55.92,55.93 - 65.41,65.42 - 73.07,73.08 - 82.50,82.51 - 92.30,>= 92.31,No
Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery,43,Registry/QCDR,Process,Y,98.51 - 99.14,99.15 - 99.99,--,--,--,--,--,100,Yes
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery,44,Registry/QCDR,Process,Y,94.44 - 96.11,96.12 - 97.23,97.24 - 98.72,98.73 - 99.99,--,--,--,100,Yes
Medication Reconciliation Post-Discharge,46,Claims,Process,Y,96.15 - 98.50,98.51 - 99.99,--,--,--,--,--,100,Yes
Medication Reconciliation Post-Discharge,46,Registry/QCDR,Process,Y,96.15 - 99.43,99.44 - 99.99,--,--,--,--,--,100,Yes
Care Plan,47,Claims,Process,Y,18.63 - 36.26,36.27 - 68.14,68.15 - 93.72,93.73 - 98.73,98.74 - 99.99,--,--,100,No
Care Plan,47,Registry/QCDR,Process,Y,44.99 - 66.16,66.17 - 77.69,77.70 - 86.58,86.59 - 93.74,93.75 - 97.69,97.70 - 99.59,99.60 - 99.99,100,No
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Claims,Process,Y,9.49 - 37.92,37.93 - 81.64,81.65 - 98.04,98.05 - 99.99,--,--,--,100,Yes
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Registry/QCDR,Process,Y,41.23 - 59.05,59.06 - 71.69,71.70 - 81.47,81.48 - 89.32,89.33 - 95.82,95.83 - 99.31,99.32 - 99.99,100,No
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Claims,Process,Y,85.00 - 94.73,94.74 - 98.52,98.53 - 99.99,--,--,--,--,100,Yes
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Registry/QCDR,Process,Y,87.50 - 93.54,93.55 - 97.43,97.44 - 99.99,--,--,--,--,100,Yes
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Claims,Process,Y,21.74 - 52.37,52.38 - 81.81,81.82 - 95.82,95.83 - 99.99,--,--,--,100,Yes
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Registry/QCDR,Process,Y,69.23 - 77.00,77.01 - 82.97,82.98 - 87.94,87.95 - 93.32,93.33 - 95.69,95.70 - 98.36,98.37 - 99.99,100,No
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,Claims,Process,Y,99.03 - 99.99,--,--,--,--,--,--,100,Yes
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,Registry/QCDR,Process,Y,84.21 - 93.97,93.98 - 96.14,96.15 - 97.81,97.82 - 99.99,--,--,--,100,Yes
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,EHR,Process,Y,74.00 - 82.42,82.43 - 87.90,87.91 - 91.29,91.30 - 93.99,94.00 - 95.99,96.00 - 98.92,98.93 - 99.99,100,No
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,Registry/QCDR,Process,Y,74.19 - 89.18,89.19 - 93.54,93.55 - 99.99,--,--,--,--,100,Yes
Appropriate Testing for Children with Pharyngitis,66,EHR,Process,Y,43.33 - 56.18,56.19 - 66.66,66.67 - 74.74,74.75 - 80.51,80.52 - 84.43,84.44 - 87.29,87.30 - 91.88,>= 91.89,No
Appropriate Testing for Children with Pharyngitis,66,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow,67,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy,68,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hematology: Multiple Myeloma: Treatment with Bisphosphonates,69,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry,70,Registry/QCDR,Process,Y,97.14 - 99.99,--,--,--,--,--,--,100,Yes
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,Claims,Process,Y,85.37 - 95.23,95.24 - 98.04,98.05 - 99.99,--,--,--,--,100,Yes
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,Registry/QCDR,Process,Y,91.85 - 96.14,96.15 - 98.88,98.89 - 99.99,--,--,--,--,100,Yes
Acute Otitis Externa (AOE): Topical Therapy,91,Claims,Process,Y,61.54 - 72.72,72.73 - 86.35,86.36 - 95.82,95.83 - 98.38,98.39 - 99.99,--,--,100,Yes
Acute Otitis Externa (AOE): Topical Therapy,91,Registry/QCDR,Process,Y,59.26 - 69.99,70.00 - 74.99,75.00 - 80.83,80.84 - 86.20,86.21 - 92.30,92.31 - 95.44,95.45 - 99.99,100,No
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Claims,Process,Y,88.37 - 95.99,96.00 - 97.49,97.50 - 99.99,--,--,--,--,100,Yes
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Registry/QCDR,Process,Y,82.80 - 90.47,90.48 - 94.43,94.44 - 97.61,97.62 - 99.99,--,--,--,100,Yes
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,99,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,99,Registry/QCDR,Process,Y,99.39 - 99.99,--,--,--,--,--,--,100,Yes
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,100,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,100,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,EHR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,Registry/QCDR,Process,Y,98.92 - 99.99,--,--,--,--,--,--,100,Yes
Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer,104,Registry/QCDR,Process,Y,84.85 - 94.11,94.12 - 95.87,95.88 - 99.99,--,--,--,--,100,Yes
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,EHR,Process,Y,22.86 - 51.99,52.00 - 74.42,74.43 - 84.92,84.93 - 88.45,88.46 - 92.80,92.81 - 95.50,95.51 - 96.47,>= 96.48,No
Osteoarthritis (OA): Function and Pain Assessment,109,Claims,Process,Y,89.34 - 96.87,96.88 - 98.73,98.74 - 99.71,99.72 - 99.99,--,--,--,100,Yes
Osteoarthritis (OA): Function and Pain Assessment,109,Registry/QCDR,Process,Y,15.38 - 35.32,35.33 - 64.99,65.00 - 84.89,84.90 - 95.18,95.19 - 99.99,--,--,100,No
Preventive Care and Screening: Influenza Immunization,110,Claims,Process,Y,23.29 - 33.13,33.14 - 46.93,46.94 - 62.62,62.63 - 74.35,74.36 - 86.05,86.06 - 97.34,97.35 - 99.99,100,No
Preventive Care and Screening: Influenza Immunization,110,EHR,Process,Y,14.55 - 21.83,21.84 - 29.00,29.01 - 35.99,36.00 - 43.53,43.54 - 52.13,52.14 - 63.12,63.13 - 78.42,>= 78.43,No
Preventive Care and Screening: Influenza Immunization,110,Registry/QCDR,Process,Y,26.89 - 40.48,40.49 - 49.99,50.00 - 57.06,57.07 - 64.78,64.79 - 73.07,73.08 - 82.70,82.71 - 96.43,>= 96.44,No
Preventive Care and Screening: Influenza Immunization,110,cmsWebInterface,Process,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
Pneumococcal Vaccination Status for Older Adults,111,Claims,Process,Y,44.78 - 55.87,55.88 - 65.57,65.58 - 73.27,73.28 - 80.67,80.68 - 87.34,87.35 - 93.84,93.85 - 99.68,>= 99.69,No
Pneumococcal Vaccination Status for Older Adults,111,EHR,Process,Y,15.40 - 25.61,25.62 - 37.30,37.31 - 47.48,47.49 - 56.46,56.47 - 65.52,65.53 - 75.08,75.09 - 85.70,>= 85.71,No
Pneumococcal Vaccination Status for Older Adults,111,Registry/QCDR,Process,Y,29.93 - 45.27,45.28 - 55.09,55.10 - 62.58,62.59 - 69.99,70.00 - 76.96,76.97 - 83.99,84.00 - 92.88,>= 92.89,No
Pneumococcal Vaccination Status for Older Adults,111,cmsWebInterface,Process,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
Breast Cancer Screening,112,Claims,Process,Y,33.68 - 45.35,45.36 - 53.21,53.22 - 60.28,60.29 - 67.83,67.84 - 76.55,76.56 - 89.23,89.24 - 99.99,100,No
Breast Cancer Screening,112,EHR,Process,Y,19.19 - 31.97,31.98 - 40.58,40.59 - 48.40,48.41 - 55.73,55.74 - 63.12,63.13 - 70.05,70.06 - 78.94,>= 78.95,No
Breast Cancer Screening,112,Registry/QCDR,Process,Y,38.69 - 52.53,52.54 - 60.13,60.14 - 65.18,65.19 - 70.17,70.18 - 76.01,76.02 - 82.72,82.73 - 92.04,>= 92.05,No
Breast Cancer Screening,112,cmsWebInterface,Process,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
Colorectal Cancer Screening,113,Claims,Process,Y,32.69 - 43.68,43.69 - 55.15,55.16 - 66.09,66.10 - 77.36,77.37 - 86.63,86.64 - 94.51,94.52 - 99.99,100,No
Colorectal Cancer Screening,113,EHR,Process,Y,12.61 - 23.91,23.92 - 34.31,34.32 - 44.54,44.55 - 54.09,54.10 - 63.63,63.64 - 73.09,73.10 - 83.14,>= 83.15,No
Colorectal Cancer Screening,113,Registry/QCDR,Process,Y,37.55 - 53.00,53.01 - 59.91,59.92 - 66.20,66.21 - 73.07,73.08 - 79.48,79.49 - 86.42,86.43 - 93.81,>= 93.82,No
Colorectal Cancer Screening,113,cmsWebInterface,Process,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis,116,Registry/QCDR,Process,Y,23.90 - 30.87,30.88 - 38.77,38.78 - 58.80,58.81 - 99.99,--,--,--,100,No
Diabetes: Eye Exam,117,Claims,Process,Y,88.98 - 98.44,98.45 - 99.99,--,--,--,--,--,100,Yes
Diabetes: Eye Exam,117,EHR,Process,Y,84.83 - 92.85,92.86 - 95.32,95.33 - 96.96,96.97 - 98.19,98.20 - 99.17,99.18 - 99.82,99.83 - 99.99,100,Yes
Diabetes: Eye Exam,117,Registry/QCDR,Process,Y,80.91 - 92.85,92.86 - 96.53,96.54 - 98.70,98.71 - 99.99,--,--,--,100,Yes
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%),118,Registry/QCDR,Process,Y,74.37 - 77.03,77.04 - 79.84,79.85 - 82.29,82.30 - 84.90,84.91 - 87.31,87.32 - 89.99,90.00 - 95.44,>= 95.45,No
Diabetes: Medical Attention for Nephropathy,119,EHR,Process,Y,64.29 - 70.20,70.21 - 75.27,75.28 - 79.68,79.69 - 83.49,83.50 - 87.36,87.37 - 91.17,91.18 - 94.99,>= 95.00,No
Diabetes: Medical Attention for Nephropathy,119,Registry/QCDR,Process,Y,72.00 - 76.58,76.59 - 80.84,80.85 - 84.02,84.03 - 86.91,86.92 - 90.09,90.10 - 93.23,93.24 - 97.66,>= 97.67,No
Adult Kidney Disease: Blood Pressure Management,122,Registry/QCDR, Intermediate Outcome,Y,69.20 - 79.16,79.17 - 90.69,90.70 - 95.08,95.09 - 96.47,96.48 - 97.66,97.67 - 98.73,98.74 - 99.99,100,No
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,Registry/QCDR,Process,Y,16.47 - 37.63,37.64 - 54.54,54.55 - 66.98,66.99 - 77.26,77.27 - 85.10,85.11 - 94.55,94.56 - 99.99,100,No
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,Registry/QCDR,Process,Y,11.75 - 28.11,28.12 - 45.27,45.28 - 61.51,61.52 - 72.15,72.16 - 82.77,82.78 - 94.28,94.29 - 99.99,100,No
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Claims,Process,Y,43.20 - 48.42,48.43 - 58.92,58.93 - 83.56,83.57 - 96.60,96.61 - 99.53,99.54 - 99.99,--,100,No
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,EHR,Process,Y,28.22 - 31.92,31.93 - 35.34,35.35 - 38.76,38.77 - 42.88,42.89 - 49.18,49.19 - 64.83,64.84 - 85.93,>= 85.94,No
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Registry/QCDR,Process,Y,45.12 - 52.05,52.06 - 59.99,60.00 - 68.74,68.75 - 77.77,77.78 - 86.07,86.08 - 92.85,92.86 - 99.42,>= 99.43,No
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,cmsWebInterface,Process,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
Documentation of Current Medications in the Medical Record,130,Claims,Process,Y,97.20 - 99.23,99.24 - 99.79,99.80 - 99.99,--,--,--,--,100,Yes
Documentation of Current Medications in the Medical Record,130,EHR,Process,Y,86.25 - 91.91,91.92 - 94.85,94.86 - 96.69,96.70 - 97.98,97.99 - 98.87,98.88 - 99.54,99.55 - 99.95,>= 99.96,Yes
Documentation of Current Medications in the Medical Record,130,Registry/QCDR,Process,Y,77.08 - 90.22,90.23 - 95.97,95.98 - 98.60,98.61 - 99.69,99.70 - 99.99,--,--,100,Yes
Pain Assessment and Follow-Up,131,Claims,Process,Y,79.10 - 96.36,96.37 - 99.37,99.38 - 99.91,99.92 - 99.99,--,--,--,100,Yes
Pain Assessment and Follow-Up,131,Registry/QCDR,Process,Y,20.00 - 49.79,49.80 - 77.66,77.67 - 88.49,88.50 - 95.53,95.54 - 99.33,99.34 - 99.99,--,100,No
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,Claims,Process,Y,17.13 - 29.27,29.28 - 65.00,65.01 - 91.46,91.47 - 99.34,99.35 - 99.99,--,--,100,No
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,EHR,Process,Y,0.51 -  1.29,1.30 -  5.09,5.10 - 12.51,12.52 - 25.60,25.61 - 42.30,42.31 - 64.36,64.37 - 83.73,>= 83.74,No
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,Registry/QCDR,Process,Y,28.44 - 53.24,53.25 - 62.81,62.82 - 71.15,71.16 - 79.90,79.91 - 88.69,88.70 - 96.42,96.43 - 99.99,100,No
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,cmsWebInterface,Process,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
Melanoma: Continuity of Care - Recall System,137,Registry/QCDR,Structure,Y,87.50 - 93.64,93.65 - 96.96,96.97 - 99.99,--,--,--,--,100,No
Melanoma: Coordination of Care,138,Registry/QCDR,Process,Y,52.38 - 78.97,78.98 - 88.88,88.89 - 95.54,95.55 - 99.99,--,--,--,100,Yes
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement,140,Claims,Process,Y,97.33 - 99.99,--,--,--,--,--,--,100,Yes
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement,140,Registry/QCDR,Process,Y,35.90 - 57.88,57.89 - 71.75,71.76 - 86.38,86.39 - 94.22,94.23 - 98.31,98.32 - 99.99,--,100,No
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Claims,Outcome,Y,--,--,--,--,--,--,--,100,Yes
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Registry/QCDR,Outcome,Y,69.40 - 86.96,86.97 - 95.04,95.05 - 97.95,97.96 - 99.64,99.65 - 99.99,--,--,100,No
Oncology: Medical and Radiation - Pain Intensity Quantified,143,EHR,Process,Y,82.07 - 91.90,91.91 - 96.54,96.55 - 99.07,99.08 - 99.86,99.87 - 99.99,--,--,100,Yes
Oncology: Medical and Radiation - Pain Intensity Quantified,143,Registry/QCDR,Process,Y,82.03 - 90.76,90.77 - 95.39,95.40 - 97.56,97.57 - 99.09,99.10 - 99.99,--,--,100,Yes
Oncology: Medical and Radiation - Plan of Care for Pain,144,Registry/QCDR,Process,Y,91.74 - 97.13,97.14 - 98.60,98.61 - 99.99,--,--,--,--,100,Yes
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy,145,Claims,Process,Y,47.89 - 63.88,63.89 - 74.90,74.91 - 82.34,82.35 - 87.99,88.00 - 92.58,92.59 - 96.54,96.55 - 99.99,100,No
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy,145,Registry/QCDR,Process,Y,71.91 - 81.24,81.25 - 87.09,87.10 - 91.66,91.67 - 95.68,95.69 - 98.67,98.68 - 99.99,--,100,No
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,Claims,Process,Y,0.23 -  0.01,--,--,--,--,--,--,0,Yes
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,Registry/QCDR,Process,Y,0.31 -  0.05,0.04 -  0.01,--,--,--,--,--,0,Yes
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Claims,Process,Y,66.67 - 79.16,79.17 - 87.49,87.50 - 93.23,93.24 - 96.54,96.55 - 99.99,--,--,100,No
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Registry/QCDR,Process,Y,83.67 - 90.71,90.72 - 95.41,95.42 - 97.82,97.83 - 99.99,--,--,--,100,Yes
Falls: Risk Assessment,154,Claims,Process,Y,96.84 - 99.99,--,--,--,--,--,--,100,Yes
Falls: Risk Assessment,154,Registry/QCDR,Process,Y,49.22 - 72.83,72.84 - 84.61,84.62 - 95.23,95.24 - 99.88,99.89 - 99.99,--,--,100,Yes
Falls: Plan of Care,155,Claims,Process,Y,42.25 - 61.32,61.33 - 87.64,87.65 - 98.89,98.90 - 99.99,--,--,--,100,Yes
Falls: Plan of Care,155,Registry/QCDR,Process,Y,46.15 - 75.12,75.13 - 89.18,89.19 - 94.16,94.17 - 97.32,97.33 - 99.99,--,--,100,No
Oncology: Radiation Dose Limits to Normal Tissues,156,Claims,Process,N,--,--,--,--,--,--,--,--,--
Oncology: Radiation Dose Limits to Normal Tissues,156,Registry/QCDR,Process,Y,95.87 - 98.94,98.95 - 99.99,--,--,--,--,--,100,Yes
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis,160,EHR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes: Foot Exam,163,EHR,Process,Y,9.38 - 16.32,16.33 - 24.01,24.02 - 31.57,31.58 - 44.65,44.66 - 59.08,59.09 - 69.43,69.44 - 79.71,>= 79.72,No
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,164,Registry/QCDR,Outcome,Y,12.39 -  9.87,9.86 -  8.74,8.73 -  6.80,6.79 -  5.35,5.34 -  4.23,4.22 -  3.04,3.03 -  1.35,<=  1.34,No
Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate,165,Registry/QCDR,Outcome,Y,0.54 -  0.01,--,--,--,--,--,--,0,Yes
Coronary Artery Bypass Graft (CABG): Stroke,166,Registry/QCDR,Outcome,Y,2.53 -  1.86,1.85 -  1.36,1.35 -  0.88,0.87 -  0.01,--,--,--,0,Yes
Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure,167,Registry/QCDR,Outcome,Y,3.74 -  2.79,2.78 -  2.18,2.17 -  1.68,1.67 -  1.19,1.18 -  0.01,--,--,0,Yes
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration,168,Registry/QCDR,Outcome,Y,3.85 -  3.29,3.28 -  2.68,2.67 -  2.06,2.05 -  1.50,1.49 -  0.95,0.94 -  0.01,--,0,No
Rheumatoid Arthritis (RA): Tuberculosis Screening,176,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rheumatoid Arthritis (RA): Functional Status Assessment,178,Registry/QCDR,Process,Y,48.99 - 68.70,68.71 - 81.07,81.08 - 92.77,92.78 - 96.03,96.04 - 99.59,99.60 - 99.99,--,100,No
Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis,179,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Elder Maltreatment Screen and Follow-Up Plan,181,Claims,Process,Y,82.12 - 99.60,99.61 - 99.99,--,--,--,--,--,100,Yes
Elder Maltreatment Screen and Follow-Up Plan,181,Registry/QCDR,Process,Y,51.20 - 75.53,75.54 - 83.75,83.76 - 90.28,90.29 - 95.70,95.71 - 98.97,98.98 - 99.99,--,100,No
Functional Outcome Assessment,182,Claims,Process,Y,99.95 - 99.99,--,--,--,--,--,--,100,Yes
Functional Outcome Assessment,182,Registry/QCDR,Process,Y,94.95 - 97.20,97.21 - 99.77,99.78 - 99.99,--,--,--,--,100,Yes
Colonoscopy Interval for Patients with a History of Adenomatous Polyps.- Avoidance of Inappropriate Use,185,Claims,Process,Y,98.00 - 99.99,--,--,--,--,--,--,100,Yes
Colonoscopy Interval for Patients with a History of Adenomatous Polyps.- Avoidance of Inappropriate Use,185,Registry/QCDR,Process,Y,90.91 - 95.99,96.00 - 97.49,97.50 - 99.64,99.65 - 99.99,--,--,--,100,Yes
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,Registry/QCDR,Process,Y,52.63 - 57.47,57.48 - 63.88,63.89 - 71.00,71.01 - 80.55,80.56 - 96.52,96.53 - 99.99,--,100,No
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,EHR,Outcome,Y,83.33 - 88.82,88.83 - 91.81,91.82 - 94.11,94.12 - 95.69,95.70 - 96.88,96.89 - 97.98,97.99 - 99.31,>= 99.32,No
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,Registry/QCDR,Outcome,Y,75.68 - 84.91,84.92 - 91.10,91.11 - 94.35,94.36 - 96.46,96.47 - 97.79,97.80 - 99.99,--,100,No
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,EHR,Outcome,Y,0.33 -  0.01,--,--,--,--,--,--,0,Yes
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,Registry/QCDR,Outcome,Y,0.50 -  0.18,0.17 -  0.01,--,--,--,--,--,0,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Claims,Process,Y,85.94 - 92.58,92.59 - 95.91,95.92 - 97.99,98.00 - 99.46,99.47 - 99.99,--,--,100,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Registry/QCDR,Process,Y,91.92 - 96.04,96.05 - 98.27,98.28 - 99.99,--,--,--,--,100,Yes
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet,204,Claims,Process,Y,83.87 - 86.90,86.91 - 89.00,89.01 - 90.90,90.91 - 92.65,92.66 - 94.58,94.59 - 97.01,97.02 - 99.99,100,No
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet,204,EHR,Process,Y,53.33 - 61.75,61.76 - 68.32,68.33 - 73.23,73.24 - 77.10,77.11 - 80.60,80.61 - 83.91,83.92 - 87.92,>= 87.93,No
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet,204,Registry/QCDR,Process,Y,76.89 - 81.70,81.71 - 84.61,84.62 - 87.16,87.17 - 89.51,89.52 - 91.87,91.88 - 94.89,94.90 - 99.99,100,No
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet,204,cmsWebInterface,Process,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
"HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis",205,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Knee Impairments,217,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Hip Impairments,218,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Foot or Ankle Impairments,219,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Lumbar Impairments,220,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Shoulder Impairments,221,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Functional Status Change for Patients with Elbow, Wrist or Hand Impairments",222,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with General Orthopaedic Impairments,223,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Melanoma: Overutilization of Imaging Studies in Melanoma,224,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Radiology: Reminder System for Screening Mammograms,225,Claims,Structure,Y,94.20 - 98.22,98.23 - 99.67,99.68 - 99.99,--,--,--,--,100,No
Radiology: Reminder System for Screening Mammograms,225,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100,Yes
Controlling High Blood Pressure,236,Claims, Intermediate Outcome,Y,58.02 - 63.90,63.91 - 68.36,68.37 - 72.91,72.92 - 76.91,76.92 - 81.65,81.66 - 86.95,86.96 - 94.06,>= 94.07,No
Controlling High Blood Pressure,236,EHR, Intermediate Outcome,Y,51.10 - 56.51,56.52 - 60.77,60.78 - 64.28,64.29 - 67.46,67.47 - 70.93,70.94 - 74.88,74.89 - 80.42,>= 80.43,No
Controlling High Blood Pressure,236,Registry/QCDR, Intermediate Outcome,Y,56.36 - 62.91,62.92 - 67.53,67.54 - 70.68,70.69 - 73.78,73.79 - 77.45,77.46 - 82.12,82.13 - 88.58,>= 88.59,No
Controlling High Blood Pressure,236,cmsWebInterface, Intermediate Outcome,Y, --,30.00 - 39.99,40.00 - 49.99,50.00 - 59.99,60.00 - 69.99,70.00 - 79.99,80.00 - 89.99,>= 90.00,No
Use of High-Risk Medications in the Elderly,238,EHR,Process,Y,12.02 -  6.84,6.83 -  3.53,3.52 -  1.50,1.49 -  0.49,0.48 -  0.01,--,--,0,Yes
Use of High-Risk Medications in the Elderly,238,Registry/QCDR,Process,Y,11.54 -  7.33,7.32 -  4.11,4.10 -  1.94,1.93 -  0.77,0.76 -  0.24,0.23 -  0.01,--,0,Yes
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,EHR,Process,Y,21.69 - 26.09,26.10 - 28.86,28.87 - 30.47,30.48 - 31.76,31.77 - 32.65,32.66 - 33.32,33.33 - 40.77,>= 40.78,No
Childhood Immunization Status,240,EHR,Process,Y,4.35 -  8.84,8.85 - 11.95,11.96 - 16.16,16.17 - 23.80,23.81 - 31.25,31.26 - 38.79,38.80 - 50.87,>= 50.88,No
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Barrett's Esophagus,249,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Barrett's Esophagus,249,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Radical Prostatectomy Pathology Reporting,250,Claims,Process,N,--,--,--,--,--,--,--,--,--
Radical Prostatectomy Pathology Reporting,250,Registry/QCDR,Process,Y,97.28 - 99.99,--,--,--,--,--,--,100,Yes
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients,251,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients,251,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Claims,Process,N,--,--,--,--,--,--,--,--,--
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Registry/QCDR,Process,Y,99.51 - 99.99,--,--,--,--,--,--,100,Yes
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Claims,Process,N,--,--,--,--,--,--,--,--,--
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Statin Therapy at Discharge after Lower Extremity Bypass (LEB),257,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7),258,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post Operative Day #2),259,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)",260,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Claims,Process,N,--,--,--,--,--,--,--,--,--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Image Confirmation of Successful Excision of Image-Localized Breast Lesion,262,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Preoperative Diagnosis of Breast Cancer,263,Registry/QCDR,Process,Y,98.98 - 99.99,--,--,--,--,--,--,100,Yes
Sentinel Lymph Node Biopsy for Invasive Breast Cancer,264,Registry/QCDR,Process,Y,97.87 - 98.98,98.99 - 99.99,--,--,--,--,--,100,Yes
Biopsy Follow-Up,265,Registry/QCDR,Process,Y,66.67 - 85.70,85.71 - 92.58,92.59 - 97.80,97.81 - 99.99,--,--,--,100,Yes
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Claims,Process,N,--,--,--,--,--,--,--,--,--
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment,271,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy,275,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sleep Apnea: Assessment of Sleep Symptoms,276,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sleep Apnea: Severity Assessment at Initial Diagnosis,277,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sleep Apnea: Positive Airway Pressure Therapy Prescribed,278,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy,279,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Dementia: Cognitive Assessment,281,EHR,Process,Y,33.33 - 52.77,52.78 - 59.08,59.09 - 69.41,69.42 - 77.77,77.78 - 86.89,86.90 - 95.23,95.24 - 99.99,100,No
Dementia: Functional Status Assessment,282,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management .,283,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Dementia: Safety Concerns Screening and Mitigation Recommendations or Referral for Patients with Dementia,286,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Dementia: Caregiver Education and Support,288,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease,290,Registry/QCDR,Process,Y,75.76 - 80.76,80.77 - 94.86,94.87 - 95.44,95.45 - 96.66,96.67 - 99.09,99.10 - 99.99,--,100,Yes
Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment,291,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Parkinson's Disease: Rehabilitative Therapy Options,293,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery,303,Registry/QCDR,Outcome,Y,13.16 - 33.32,33.33 - 51.91,51.92 - 72.96,72.97 - 82.75,82.76 - 88.32,88.33 - 92.51,92.52 - 98.91,>= 98.92,No
Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery,304,Registry/QCDR,Outcome,Y,7.69 - 29.99,30.00 - 49.99,50.00 - 68.74,68.75 - 80.84,80.85 - 86.26,86.27 - 92.16,92.17 - 99.99,100,No
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment,305,EHR,Process,Y,0.49 -  0.65,0.66 -  0.77,0.78 -  0.89,0.90 -  2.10,2.11 -  2.71,2.72 -  4.06,4.07 - 14.48,>= 14.49,No
Cervical Cancer Screening,309,EHR,Process,Y,8.82 - 14.57,14.58 - 20.88,20.89 - 28.29,28.30 - 37.64,37.65 - 47.75,47.76 - 58.15,58.16 - 71.63,>= 71.64,No
Chlamydia Screening for Women,310,EHR,Process,Y,13.89 - 19.99,20.00 - 28.12,28.13 - 32.80,32.81 - 38.83,38.84 - 48.14,48.15 - 55.17,55.18 - 63.99,>= 64.00,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Claims,Process,Y,49.53 - 57.74,57.75 - 66.45,66.46 - 78.56,78.57 - 90.52,90.53 - 98.16,98.17 - 99.99,--,100,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,EHR,Process,Y,16.53 - 20.40,20.41 - 23.94,23.95 - 26.93,26.94 - 29.99,30.00 - 33.32,33.33 - 37.61,37.62 - 45.98,>= 45.99,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Registry/QCDR,Process,Y,35.65 - 51.15,51.16 - 64.21,64.22 - 71.25,71.26 - 76.46,76.47 - 81.40,81.41 - 88.06,88.07 - 97.68,>= 97.69,No
Falls: Screening for Future Fall Risk,318,EHR,Process,Y,9.14 - 20.16,20.17 - 33.70,33.71 - 48.36,48.37 - 65.67,65.68 - 81.76,81.77 - 93.39,93.40 - 98.80,>= 98.81,No
Falls: Screening for Future Fall Risk,318,cmsWebInterface,Process,Y, --,43.42 - 50.41,50.42 - 58.44,58.45 - 65.99,66.00 - 73.38,73.39 - 81.78,81.79 - 90.72,>= 90.73,No
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Claims,Process,Y,91.51 - 96.40,96.41 - 99.99,--,--,--,--,--,100,Yes
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Registry/QCDR,Process,Y,87.30 - 91.48,91.49 - 94.25,94.26 - 96.21,96.22 - 98.68,98.69 - 99.99,--,--,100,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,322,Registry/QCDR,Efficiency,Y,3.45 -  0.93,0.92 -  0.01,--,--,--,--,--,0,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),323,Registry/QCDR,Efficiency,Y,0.92 -  0.01,--,--,--,--,--,--,0,Yes
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,Registry/QCDR,Efficiency,Y,17.89 -  2.36,2.35 -  0.01,--,--,--,--,--,0,No
Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions,325,Registry/QCDR,Process,Y,66.67 - 82.95,82.96 - 91.52,91.53 - 98.04,98.05 - 99.99,--,--,--,100,Yes
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Claims,Process,Y,93.91 - 97.29,97.30 - 99.40,99.41 - 99.99,--,--,--,--,100,Yes
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Registry/QCDR,Process,Y,74.17 - 78.28,78.29 - 81.24,81.25 - 83.91,83.92 - 86.37,86.38 - 89.23,89.24 - 93.22,93.23 - 99.99,100,No
Pediatric Kidney Disease: Adequacy of Volume Management,327,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL,328,Registry/QCDR, Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis,329,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days,330,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Overuse),331,Registry/QCDR,Process,Y,90.10 - 84.63,84.62 - 80.59,80.58 - 68.67,68.66 - 45.11,45.10 -  9.10,9.09 -  1.23,1.22 -  0.01,0,No
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,Registry/QCDR,Process,Y,31.58 - 48.27,48.28 - 54.54,54.55 - 61.08,61.09 - 68.08,68.09 - 83.86,83.87 - 95.99,96.00 - 99.99,100,No
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse),333,Registry/QCDR,Efficiency,Y,3.57 -  1.89,1.88 -  0.01,--,--,--,--,--,0,Yes
Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse),334,Registry/QCDR,Efficiency,Y,3.13 -  1.40,1.39 -  0.40,0.39 -  0.01,--,--,--,--,0,Yes
Maternity Care: Elective Delivery or Early Induction Without Medical Indication at >= 37 and < 39 Weeks (Overuse),335,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Maternity Care: Post-Partum Follow-Up and Care Coordination,336,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Tuberculosis (TB) Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier",337,Registry/QCDR,Process,Y,54.21 - 79.24,79.25 - 87.23,87.24 - 91.75,91.76 - 95.40,95.41 - 96.74,96.75 - 99.99,--,100,No
HIV Viral Load Suppression,338,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
HIV Medical Visit Frequency,340,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pain Brought Under Control Within 48 Hours,342,Registry/QCDR,Outcome,Y,93.22 - 99.99,--,--,--,--,--,--,100,No
Screening Colonoscopy Adenoma Detection Rate,343,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)",344,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS),345,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA),346,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital,347,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate,348,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,350,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation,351,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet,352,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report,353,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Anastomotic Leak Intervention,354,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Reoperation within the 30 Day Postoperative Period,355,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Site Infection (SSI),357,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient-Centered Surgical Risk Assessment and Communication,358,Registry/QCDR,Process,Y,31.03 - 67.99,68.00 - 91.05,91.06 - 97.11,97.12 - 99.99,--,--,--,100,Yes
Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computed Tomography (CT) Imaging Description,359,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry,361,Registry/QCDR,Structure,N,--,--,--,--,--,--,--,--,--
Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes,362,Registry/QCDR,Structure,N,--,--,--,--,--,--,--,--,--
"Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Studies Through a Secure, Authorized, Media-Free, Shared Archive",363,Registry/QCDR,Structure,N,--,--,--,--,--,--,--,--,--
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication,366,EHR,Process,N,--,--,--,--,--,--,--,--,--
Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use,367,EHR,Process,N,--,--,--,--,--,--,--,--,--
Pregnant women that had HBsAg testing,369,EHR,Process,N,--,--,--,--,--,--,--,--,--
Depression Remission at Twelve Months,370,EHR,Outcome,N,--,--,--,--,--,--,--,--,--
Depression Remission at Twelve Months,370,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Depression Utilization of the PHQ-9 Tool,371,EHR,Process,Y,1.65 -  2.45,2.46 -  3.32,3.33 -  4.32,4.33 -  5.59,5.60 -  8.32,8.33 - 14.99,15.00 - 48.14,>= 48.15,No
Maternal Depression Screening,372,EHR,Process,N,--,--,--,--,--,--,--,--,--
Hypertension: Improvement in Blood Pressure,373,EHR,Intermediate Outcome,Y,17.07 - 22.21,22.22 - 27.26,27.27 - 32.32,32.33 - 37.88,37.89 - 42.85,42.86 - 48.47,48.48 - 55.99,>= 56.00,No
Closing the Referral Loop: Receipt of Specialist Report,374,EHR,Process,Y,14.29 - 24.13,24.14 - 33.57,33.58 - 43.65,43.66 - 54.33,54.34 - 63.78,63.79 - 74.99,75.00 - 88.63,>= 88.64,No
Closing the Referral Loop: Receipt of Specialist Report,374,Registry/QCDR,Process,Y,65.22 - 99.99,--,--,--,--,--,--,100,Yes
Functional Status Assessment for Total Knee Replacement,375,EHR,Process,Y,5.08 - 14.80,14.81 - 25.76,25.77 - 36.51,36.52 - 44.73,44.74 - 51.27,51.28 - 60.55,60.56 - 79.99,>= 80.00,No
Functional Status Assessment for Total Hip Replacement,376,EHR,Process,Y,10.34 - 26.08,26.09 - 41.66,41.67 - 47.82,47.83 - 56.50,56.51 - 61.15,61.16 - 64.99,65.00 - 72.72,>= 72.73,No
Functional Status Assessments for Congestive Heart Failure,377,EHR,Process,N,--,--,--,--,--,--,--,--,--
Children Who Have Dental Decay or Cavities,378,EHR,Outcome,Y,--,--,--,--,--,--,--,0,Yes
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,EHR,Process,Y,0.36 -  0.54,0.55 -  0.78,0.79 -  1.11,1.12 -  2.03,2.04 -  4.40,4.41 -  5.09,5.10 -  7.36,>=  7.37,No
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,EHR,Process,N,--,--,--,--,--,--,--,--,--
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,Registry/QCDR,Intermediate Outcome,Y,68.57 - 77.77,77.78 - 88.19,88.20 - 93.99,94.00 - 98.85,98.86 - 99.99,--,--,100,No
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences,386,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users,387,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy),388,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0,Yes
Cataract Surgery: Difference Between Planned and Final Refraction,389,Registry/QCDR,Outcome,Y,13.89 - 38.23,38.24 - 58.48,58.49 - 74.99,75.00 - 82.97,82.98 - 91.90,91.91 - 96.24,96.25 - 99.99,100,No
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options,390,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Follow-Up After Hospitalization for Mental Illness (FUH),391,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation,392,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision",393,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Immunizations for Adolescents,394,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Claims,Process,Y,96.00 - 99.99,--,--,--,--,--,--,100,Yes
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Registry/QCDR,Process,Y,95.83 - 96.66,96.67 - 99.99,--,--,--,--,--,100,Yes
Lung Cancer Reporting (Resection Specimens),396,Claims,Process,N,--,--,--,--,--,--,--,--,--
Lung Cancer Reporting (Resection Specimens),396,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Melanoma Reporting,397,Claims,Process,Y,95.00 - 97.05,97.06 - 99.99,--,--,--,--,--,100,Yes
Melanoma Reporting,397,Registry/QCDR,Process,Y,97.14 - 99.99,--,--,--,--,--,--,100,Yes
Optimal Asthma Control,398,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk,400,Registry/QCDR,Process,Y,1.62 -  2.21,2.22 -  3.22,3.23 - 11.10,11.11 - 19.60,19.61 - 27.21,27.22 - 35.35,35.36 - 68.74,>= 68.75,No
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis,401,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Tobacco Use and Help with Quitting Among Adolescents,402,Registry/QCDR,Process,Y,71.85 - 75.75,75.76 - 85.70,85.71 - 89.99,90.00 - 92.58,92.59 - 95.37,95.38 - 97.55,97.56 - 99.99,100,No
Adult Kidney Disease: Referral to Hospice,403,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Anesthesiology Smoking Abstinence,404,Registry/QCDR,Intermediate Outcome,Y,42.86 - 49.99,50.00 - 61.69,61.70 - 66.66,66.67 - 73.90,73.91 - 82.60,82.61 - 91.70,91.71 - 99.99,100,No
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Claims,Process,Y,33.33 - 22.04,22.03 - 15.39,15.38 - 11.12,11.11 -  7.51,7.50 -  4.21,4.20 -  1.53,1.52 -  0.01,0,No
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Registry/QCDR,Process,Y,25.00 - 18.19,18.18 - 12.39,12.38 -  8.71,8.70 -  5.09,5.08 -  2.23,2.22 -  0.01,--,0,No
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Claims,Process,Y,45.45 - 36.01,36.00 - 30.01,30.00 - 21.63,21.62 - 15.01,15.00 -  8.71,8.70 -  4.18,4.17 -  0.01,0,No
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Registry/QCDR,Process,Y,37.32 - 21.44,21.43 - 15.64,15.63 -  6.57,6.56 -  4.12,4.11 -  1.31,1.30 -  0.01,--,0,No
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia,407,Claims,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia,407,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Opioid Therapy Follow-up Evaluation,408,Registry/QCDR,Process,Y,75.51 - 82.66,82.67 - 92.01,92.02 - 97.78,97.79 - 99.99,--,--,--,100,Yes
Clinical Outcome Post Endovascular Stroke Treatment,409,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Psoriasis: Clinical Response to Oral Systemic or Biologic Medications,410,Registry/QCDR,Outcome,Y,40.91 - 54.54,54.55 - 70.82,70.83 - 80.30,80.31 - 91.50,91.51 - 95.64,95.65 - 99.99,--,100,No
Depression Remission at Six Months,411,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Documentation of Signed Opioid Treatment Agreement,412,Registry/QCDR,Process,Y,37.14 - 70.37,70.38 - 94.28,94.29 - 99.04,99.05 - 99.99,--,--,--,100,Yes
Door to Puncture Time for Endovascular Stroke Treatment,413,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Evaluation or Interview for Risk of Opioid Misuse,414,Registry/QCDR,Process,Y,79.89 - 95.34,95.35 - 98.23,98.24 - 99.99,--,--,--,--,100,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Claims,Efficiency,Y,90.91 - 93.54,93.55 - 95.44,95.45 - 96.29,96.30 - 99.99,--,--,--,100,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Registry/QCDR,Efficiency,Y,88.52 - 90.35,90.36 - 91.79,91.80 - 94.09,94.10 - 95.41,95.42 - 96.66,96.67 - 97.82,97.83 - 99.99,100,No
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Claims,Efficiency,N,--,--,--,--,--,--,--,--,--
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Rate of Open Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) Where Patients Are Discharged Alive,417,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Osteoporosis Management in Women Who Had a Fracture,418,Claims,Process,N,--,--,--,--,--,--,--,--,--
Osteoporosis Management in Women Who Had a Fracture,418,Registry/QCDR,Process,Y,4.29 -  4.99,5.00 -  7.16,7.17 - 10.38,10.39 - 15.57,15.58 - 18.17,18.18 - 88.32,88.33 - 99.99,100,No
Overuse Of Neuroimaging For Patients With Primary Headache And A Normal Neurological Examination,419,Claims,Efficiency,N,--,--,--,--,--,--,--,--,--
Overuse Of Neuroimaging For Patients With Primary Headache And A Normal Neurological Examination,419,Registry/QCDR,Efficiency,Y,98.23 - 99.27,99.28 - 99.99,--,--,--,--,--,100,No
Varicose Vein Treatment with Saphenous Ablation: Outcome Survey,420,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal,421,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,Claims,Process,N,--,--,--,--,--,--,--,--,--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy,423,Claims,Process,N,--,--,--,--,--,--,--,--,--
Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy,423,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Perioperative Temperature Management,424,Registry/QCDR,Outcome,Y,99.63 - 99.99,--,--,--,--,--,--,100,Yes
Photodocumentation of Cecal Intubation,425,Claims,Process,Y,98.55 - 98.97,98.98 - 99.56,99.57 - 99.99,--,--,--,--,100,Yes
Photodocumentation of Cecal Intubation,425,Registry/QCDR,Process,Y,63.36 - 78.52,78.53 - 98.58,98.59 - 99.99,--,--,--,--,100,Yes
Post-Anesthetic Transfer of Care Measure: Procedure Room to a Post Anesthesia Care Unit (PACU),426,Registry/QCDR,Process,Y,99.78 - 99.99,--,--,--,--,--,--,100,Yes
Post-Anesthetic Transfer of Care: Use of Checklist or Protocol for Direct Transfer of Care from Procedure Room to Intensive Care Unit (ICU),427,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence,428,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,Claims,Process,N,--,--,--,--,--,--,--,--,--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,Registry/QCDR,Process,Y,95.99 - 98.69,98.70 - 99.99,--,--,--,--,--,100,Yes
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,Registry/QCDR,Process,Y,20.00 - 44.13,44.14 - 63.91,63.92 - 77.43,77.44 - 86.26,86.27 - 92.67,92.68 - 97.07,97.08 - 99.99,100,No
Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair,432,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair,433,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion of Patients Sustaining a Ureter Injury at the Time of any Pelvic Organ Prolapse Repair,434,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Claims,Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Claims,Process,Y,51.21 - 67.48,67.49 - 76.69,76.70 - 82.88,82.89 - 87.64,87.65 - 92.25,92.26 - 96.58,96.59 - 99.75,>= 99.76,No
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Registry/QCDR,Process,Y,64.68 - 73.79,73.80 - 81.51,81.52 - 89.00,89.01 - 98.20,98.21 - 99.99,--,--,100,No
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Claims,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,EHR,Process,N,--,--,--,--,--,--,--,--,--
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,Registry/QCDR,Process,Y,61.47 - 65.40,65.41 - 69.31,69.32 - 71.67,71.68 - 74.37,74.38 - 77.21,77.22 - 81.17,81.18 - 87.22,>= 87.23,No
Age Appropriate Screening Colonoscopy,439,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time - Pathologist to Clinician .,440,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Persistence of Beta-Blocker Treatment After a Heart Attack,442,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Recommended Cervical Cancer Screening in Adolescent Females,443,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Management for People with Asthma,444,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG),445,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Operative Mortality Stratified by the Five STS-EACTS Mortality Categories,446,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Chlamydia Screening and Follow Up,447,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Work Up Prior to Endometrial Ablation,448,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies,449,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Trastuzumab Received By Patients With AJCC Stage I (T1c) -  III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy,450,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy,451,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) 4 with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies,452,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proportion Receiving Chemotherapy in the Last 14 Days of Life,453,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of Life,454,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life,455,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion Not Admitted To Hospice,456,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proportion Admitted to Hospice for less than 3 days,457,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Average Change in Back Pain following Lumbar Discectomy / Laminotomy,459,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Average Change in Back Pain following Lumbar Fusion,460,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Average Change in Leg Pain following Lumbar Discectomy and/or Laminotomy,461,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy,462,EHR,Process,N,--,--,--,--,--,--,--,--,--
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics),463,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion (OME): Systemic Antimicrobials- Avoidance of Inappropriate Use,464,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and.Interrogation of Ovarian Arteries,465,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Developmental Screening in the First Three Years of Life,467,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Asthma: Assessment of Asthma Control ?Ambulatory Care Setting,AAAAI2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of Clinical Response to Allergen Immunotherapy within One Year,AAAAI6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year,AAAAI8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Assessment of Asthma Symptoms Prior to Administration of Allergen Immunotherapy Injection(s),AAAAI9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Asthma Assessment and Classification,AAAAI11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lung Function/Spirometry Evaluation,AAAAI12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Asthma Control: Minimal Important Difference Improvement,AAAAI17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Penicillin Allergy: Appropriate Removal or Confirmation,AAAAI18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Psoriasis: Assessment of Psoriasis Disease Activity,AAD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Psoriasis: Screening for Psoriatic Arthritis,AAD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Superficial Basal Cell Carcinoma of the Trunk for Immune Competent Patients,AAD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Squamous Cell Carcinoma in Situ or Keratoacanthoma Type Squamous Cell Carcinoma 1 cm or Smaller on the Trunk,AAD4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Biopsy: Reporting Time - Clinician to Patient,AAD5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Distal Symmetric Polyneuropathy: Prediabetes screening,AAN1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Distal Symmetric Polyneuropathy: Screening for Unhealthy Alcohol Use,AAN2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Epilepsy: Screening for Psychiatric or Behavioral Health Disorders,AAN4,Registry/QCDR,Process,Y,44.16 - 53.64,53.65 - 67.20,67.21 - 76.64,76.65 - 90.44,90.45 - 93.54,93.55 - 95.56,95.57 - 98.12,>= 98.13,No
Headache: Medication prescribed for acute migraine attack,AAN5,Registry/QCDR,Process,Y,39.50 - 43.47,43.48 - 45.29,45.30 - 49.99,50.00 - 55.81,55.82 - 59.60,59.61 - 64.72,64.73 - 74.09,>= 74.10,No
Multiple Sclerosis: Exercise and Appropriate Physical Activity Counseling for Patients with MS,AAN8,Registry/QCDR,Process,Y,9.62 - 11.82,11.83 - 18.24,18.25 - 29.22,29.23 - 42.85,42.86 - 53.77,53.78 - 59.56,59.57 - 67.29,>= 67.30,No
Querying About Symptoms of Autonomic Dysfunction for Patients with Parkinson's Disease,AAN9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Falls screening (aggregation of AAN disease specific falls measures),AAN10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Overuse of barbiturate and opioid containing medications for primary headache disorders,AAN11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment for Patients with Epilepsy,AAN12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Current MS Disability Scale Score,AAN14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment,AAN15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Falls Outcome for Patients with Parkinson's Disease,AAN16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
First line treatment for infantile spasms (IS),AAN18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Botulinum Toxin Serotype A (BoNT-A) for spasticity or dystonia,AAN19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Querying for co-morbid conditions of tic disorder (TD) and Tourette syndrome (TS),AAN20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Antihistamines or Decongestants - Avoidance of Inappropriate Use,AAO8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Avoidance of Topical Intranasal Corticosteroids,AAO11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Topical Ear Drop Monotherapy for Children with Acute Tympanostomy Tube Otorrhea,AAO12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inappropriate Use of Magnetic Resonance Imaging or Computed Tomography Scan for Bell's Palsy (Inverse Measure),AAO13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inappropriate Use of Antiviral Monotherapy for Bell's Palsy (Inverse Measure),AAO14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with cerumen impaction and a suggestive history of a non-intact tympanic membrane who receive just manual removal.,AAO15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Audiometric Evaluation for Older Adults with Hearing Loss,AAO16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss-Avoidance of Inappropriate Use,AAO17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of visits with patients with hearing aids where otoscopy is routinely performed,AAO18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Shared Decision Making for Treatment Options for Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss,AAO19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Hearing Testing,AAO20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Audiometry for Chronic Otitis Media with Effusion in Children,AAO21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who do not receive sinonasal imaging for allergic rhinitis,AAO22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who are offered intranasal corticosteroids or oral antihistamines,AAO23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who do not receive leukotriene inhibitors,AAO24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who do not receive IgG-based immunoglobulin testing,AAO25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility,AAO26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Children,AAO27,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Adults,AAO28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
All Patients Who Die an Expected Death with an ICD that Has Been Deactivated,ABFM1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patients Admitted to ICU who Have Care Preferences Documented,ABFM2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patients Treated with an Opioid Who Are Given a Bowel Regimen,ABFM3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Palliative Care - Spiritual Assessment,ABFM4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Palliative Care-Treatment Preferences,ABFM5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Palliative Care Timely Dyspnea Screening & Treatment,ABFM6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pain Brought Under Control within the first three visits,ABFM7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Measuring the Value-Functions of Primary Care: Provider Level Continuity Measure,ABFM8,Registry/QCDR,Structure,N,--,--,--,--,--,--,--,--,--
Intra-operative anesthesia safety,ABG1,Registry/QCDR,Outcome,Y,99.85 - 99.99,--,--,--,--,--,--,100,Yes
Immediate Adult Post-Operative Pain Management,ABG7,Registry/QCDR,Outcome,Y,99.93 - 99.97,99.98 - 99.99,--,--,--,--,--,100,Yes
Planned use of difficult airway equipment,ABG16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pre-operative OSA assessment,ABG21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pre-Operative Screening for GERD,ABG28,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pre-Operative Screening for Glaucoma,ABG29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pre-Operative Screening for PONV Risk,ABG30,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pre-Operative Screening for Excessive Alcohol and Recreational Drug Use,ABG31,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pain Related Quality of Life Interference,ABG32,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lower Body Functional Impairment (LBI),ABG33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mood Assessment Screening and treatment,ABG34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preoperative Assessment of Frailty,ABG35,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Corneal Abrasion,ABG36,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
HF: Patient Self Care Education,ACCPIN3,Registry/QCDR,Process,Y,57.81 - 71.42,71.43 - 78.78,78.79 - 84.84,84.85 - 89.08,89.09 - 92.58,92.59 - 95.70,95.71 - 98.47,>= 98.48,No
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,ACEP19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,ACEP20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ACEP21,Registry/QCDR,Process,Y,19.06 - 16.74,16.73 - 14.34,14.33 - 11.36,11.35 -  8.90,8.89 -  6.39,6.38 -  4.13,4.12 -  1.46,<=  1.45,No
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism,ACEP22,Registry/QCDR,Process,Y,41.67 - 44.51,44.52 - 46.33,46.34 - 49.17,49.18 - 52.33,52.34 - 56.30,56.31 - 61.01,61.02 - 65.24,>= 65.25,No
Pregnancy Test for Female Abdominal Pain Patients,ACEP24,Registry/QCDR,Process,Y,72.00 - 74.23,74.24 - 77.21,77.22 - 79.52,79.53 - 80.52,80.53 - 82.12,82.13 - 84.32,84.33 - 87.17,>= 87.18,No
Tobacco Screening and Cessation Intervention for ED patients with Cardiovascular and/or Pulmonary Conditions,ACEP25,Registry/QCDR,Process,Y,11.10 - 15.70,15.71 - 19.29,19.30 - 21.81,21.82 - 24.08,24.09 - 33.50,33.51 - 42.43,42.44 - 51.65,>= 51.66,No
Sepsis Management: Septic Shock: Repeat Lactate Level Measurement,ACEP29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sepsis Management: Septic Shock: Lactate Clearance Rate of >=10%,ACEP30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Foley Catheter Use in the Emergency Department,ACEP31,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients,ACEP32,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Supercenter EDs.(80k +),ACEP33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in High Volume EDs (60k-79,999)",ACEP35,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Average Volume EDs (40k-59,999)",ACEP36,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Moderate Volume EDs (20k-39,999)",ACEP37,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Low Volume EDs (19,999 and less)",ACEP38,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Freestanding Ends,ACEP39,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients,ACEP40,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Supercenter EDs (80k +),ACEP41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in High Volume EDs (60k-79,999)",ACEP43,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Average Volume EDs (40k-59,999)",ACEP44,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Moderate Volume EDs (20k-39,999)",ACEP45,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Low Volume EDs (19,999 and less)",ACEP46,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Freestanding EDs,ACEP47,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Sepsis Management: Septic Shock: Lactate Level Management, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screening for risk of opioid misuse/overuse,ACMT1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pregnancy test in women who receive a toxicologic consult,ACMT2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
EKG assessment in acute overdoses,ACMT3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate treatment for acetaminophen ingestions,ACMT4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment of suspected ethylene glycol or methanol exposures,ACMT5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Repeat assessment of salicylate concentrations in overdose patients,ACMT6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
High Risk Pneumococcal Vaccination,ACPGR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Tdap (Tetanus, Diphtheria, Acellular Pertussis) Vaccination",ACPGR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy,ACPGR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
COPD Exacerbation Requiring Hospital Admission: Palliative Care Evaluation,ACQR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
COPD Exacerbation: % of patients discharged from inpatient status on Long Acting Beta Agonist (LABA) bronchodilator,ACQR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
COPD: Steroids for no more than 5 days in COPD Exacerbation,ACQR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CHF Exacerbation Requiring Hospital Admission: Palliative Care Evaluation,ACQR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CHF: Document AHA/ACC staging of CHF (A-D),ACQR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"POLST Utilization: POLST form reviewed or completed for any patients with limited code status (i.e. any status other than, ""Attempt Resuscitation"" if unresponsive, pulseless and not breathing;  and ""Full Treatment"" if patient is pulseless and breathing)",ACQR6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sepsis Management: Septic Shock: Repeat Lactate Level Measurement within 6 hours,ACQR7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Stroke/TIA: % of patients discharged on antithrombotic therapy,ACQR8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Gout: Serum Urate Target,ACR7,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
CT Colonongraphy True Positive Rate,ACRAD1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening Mammography Cancer Detection Rate (CDR),ACRAD3,Registry/QCDR,Outcome,Y,3.43 -  3.86,3.87 -  4.43,4.44 -  4.78,4.79 -  5.21,5.22 -  6.16,6.17 -  7.04,7.05 -  7.55,>=  7.56,No
Screening Mammography Abnormal Interpretation Rate (Recall Rate),ACRAD5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening Mammography Positive Predictive Value 2 (PPV2 - BiopsyRecommended),ACRAD6,Registry/QCDR,Outcome,Y,19.89 - 21.61,21.62 - 25.57,25.58 - 27.77,27.78 - 29.66,29.67 - 31.59,31.60 - 36.47,36.48 - 39.57,>= 39.58,No
Screening Mammography Node Negativity Rate,ACRAD7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening Mammography Minimal Cancer Rate,ACRAD8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: Radiography,ACRAD15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRAD16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: MRI,ACRAD17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: CT,ACRAD18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: PET,ACRAD19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Cancer Detection Rate (CDR),ACRAD21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Positive Predictive Value (PPV),ACRAD22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Abnormal Interpretation Rate,ACRAD23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: Mammography,ACRAD25,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate venous access for hemodialysis,ACRAD26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of early peristomal infection following fluoroscopically guided gastrostomy tube placement,ACRAD28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of percutaneous nephrostomy tube replacement within 30 days secondary to dislodgement,ACRAD29,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Inadequate Percutaneous Image-Guided Biopsy,ACRAD30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of CT Abdomen-pelvis exams with contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD31,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of CT Chest exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD32,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of CT Head/Brain exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level,ACRAD33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preoperative Composite,ACS15,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Preventative Care and Screening: Tobacco Screening and Cessation Intervention,ACS16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative Key Medications Review for Anticoagulation Medication,ACS17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Frailty Evaluation,ACS18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Intraoperative Composite,ACS19,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Optimal Postoperative Communication Plan and Patient Care Coordination Composite,ACS20,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Post-Acute Recovery Composite,ACS21,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Unplanned Reoperation within the 30 Day Postoperative Period,ACS22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Readmission within 30 Days of Principal Procedure,ACS23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Phases of Care Patient-Reported Outcome Composite Measure,ACS24,Registry/QCDR,Patient Engagement/Experience,N,--,--,--,--,--,--,--,--,--
Surgical Site Infection (SSI),ACS25,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Trauma Initial Assessment Composite,ACSTRAUMA1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Mortality Rate Following Blunt Traumatic Injury to the Chest and/or Abdomen,ACSTRAUMA2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mortality Rate Following Penetrating Traumatic Injury to the Chest and/or Abdomen,ACSTRAUMA3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Splenic Salvage Rate,ACSTRAUMA4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Optimal Timing of Surgical or Procedural Intervention for Hemorrhage in Trauma,ACSTRAUMA5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Optimal Ratio of Blood Product Transfusion,ACSTRAUMA6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Timely Initiation of VTE Prophylaxis in Trauma Patients,ACSTRAUMA7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period,AHSQC1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Readmission or Observation Visit within the 30 Day Postoperative Period,AHSQC2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Abdominal Wall Reconstruction Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period,AHSQC6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Biologic Mesh Prosthesis Use in Low Risk Patients,AHSQC8,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Pain and Functional Status Assessment,AHSQC9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Postoperative Complications within 90 Days Following the Procedure,AJRR1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,AJRR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Venous Thromboembolic and Cardiovascular Risk Evaluation,AJRR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Comprehensive Diabetic Foot Examination,APMA1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,AQI18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Stroke,AQI41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Post-Operative Renal Failure,AQI42,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient-Reported Experience with Anesthesia,AQI48,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Adherence to Blood Conservation Guidelines for Cardiac Operations using Cardiopulmonary Bypass (CPB) - Composite,AQI49,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Application of Lung-Protective Ventilation during General Anesthesia,AQI50,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Assessment of Patients for Obstructive Sleep Apnea,AQI51,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of Anticoagulant and Antiplatelet Medications when Performing Neuraxial Anesthesia/Analgesia or Interventional Pain Procedures,AQI53,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Pencil-Point Needle for Spinal Anesthesia,AQI54,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Team-Based Implementation of a Care-and-Communication Bundle for ICU Patients,AQI55,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA),AQI56,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Safe Opioid Prescribing Practices,AQI57,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Infection Control Practices for Open Interventional Pain Procedures,AQI58,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Multimodal Pain Management,AQI59,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
New Corneal Injury Not Diagnosed Prior to Discharge,AQI60,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys,AQUA3,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Hospital re-admissions / complications within 30 days of TRUS Biopsy,AQUA8,Registry/QCDR,Outcome,Y,4.00 -  3.24,3.23 -  2.21,2.20 -  1.70,1.69 -  1.34,1.33 -  0.01,--,--,0,Yes
Benign Prostate Hyperplasia: IPSS improvement after diagnosis,AQUA12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stress Urinary Incontinence (SUI): Revision surgery within 12 months of incontinence procedure,AQUA13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stones: Repeat Shock Wave Lithotripsy (SWL) within 6 months of treatment,AQUA14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stones: Urinalysis documented 30 days before surgical stone procedures,AQUA15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease,AQUA16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Initiation of BCG 3 months of diagnosis of high-grade T1 bladder cancer and/or CIS,AQUA17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis,AQUA18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diagnosis of Type of Azoospermia and Diagnostic Testing for Obstructive Azoospermia,AQUA19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Genetic Testing  of the Azoospermic Male,AQUA20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Management of Obstructive Azoospermia,AQUA21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Bone imaging and soft tissue imaging at the time of diagnosis of metastatic CRPC,AQUA22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Blood work for patients receiving abiraterone,AQUA23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Testosterone and PSA levels checked for CRPC patients,AQUA24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Prednisone for CRPC patients on abiraterone,AQUA25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Benign Prostate Hyperplasia Care: Benign Prostate Hyperplasia,AQUA26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Testing for Vasectomy Patients,AQUA27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hypogonadism: Testosterone and hematocrit within 6 months of starting testosterone replacement,AQUA28,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Patient Report of Urinary function after treatment,AQUA29,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Patient Report of Sexual function after treatment,AQUA30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Antipsychotic Use in Persons with Dementia,ARCO3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Risk Standardized Mortality Rate within 30 days following Trauma Operation,ARCO10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation within 45 minutes of ED Arrival,ARCO11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
STK-01: Venous Thromboembolism (VTE) Prophylaxis,ARCO12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
STK 02: Ischemic stroke patients management -,ARCO13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Diabetes: Nutritional, Weight Loss Counseling, Reduction of Sedentary Behavior",ARCO15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Dyspnea or Heart Failure: Use of BNP or NT- pro BNP screening,ARCO16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Heart Failure: Use of Aldosterone Antagonists and Diuretics for Symptom Control,ARCO17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Heart Failure: Counseling on Self-care, Including Monitoring Blood Pressure, Weight, Sodium Intake, and Physical Activity",ARCO18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Promoting self-care for prevention and management of chronic conditions,ARCO19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Percentage of patients using self-monitoring with mobile technology or eHealth solutions to manage their diabetes, hypertension, sodium intake, nutritional status, physical activity, tobacco use, alcohol use, and sedentary behaviors",ARCO20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Surgeon assessment for hereditary cause of breast cancer,ASBS1,Registry/QCDR,Process,Y,99.34 - 99.63,99.64 - 99.99,--,--,--,--,--,100,Yes
Unplanned 30 day re-operation after mastectomy,ASBS7,Registry/QCDR,Outcome,Y,97.62 - 98.52,98.53 - 99.99,--,--,--,--,--,100,Yes
Management of the axilla in breast cancer patients undergoing breast conserving surgery with a positive sentinel node biopsy,ASBS10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Return to the operating room for re-excision of previous microscopically negative margins in invasive breast cancer patients undergoing breast conserving therapy,ASBS12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Sentinel Node Biopsy for Patients with Ductal Carcinoma in Situ Alone,ASBS13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Recommendation of Neoadjuvant Chemotherapy for Her2Neu positive invasive breast cancers that are >2.0cm in size and/or have needle biopsy proven axillary metastases.,ASBS14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,ASNC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),ASNC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",ASNC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Imaging Protocols for SPECT and PET MPI studies - Use of stress only protocol,ASNC19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SPECT-MPI studies performed without the use of thallium,ASNC20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study appropriate imaging protocol selection for morbidly obese patients,ASNC21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI studies reporting Left Ventricular Ejection Fraction,ASNC22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study clinical utilization of Attenuation Correction image acquisition,ASNC23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study utilization of exercise as a stressor,ASNC24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study adequate exercise testing performed,ASNC25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI studies meeting appropriate use criteria,ASNC26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI studies not Equivocal,ASNC27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Effective dose less than or equal to 9 millisieverts as per ASNC guideline recommendations,ASNC28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI study documentation of stress perfusion defects,ASNC29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Transthoracic Echo (TTE) studies meeting appropriate use criteria.,ASNC30,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Transthoracic Echo (TTE) studies reporting pulmonary artery pressures, 100% views, contrast use  .",ASNC31,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Train of Four Monitor Documented After Last Dose of Non-depolarizing Neuromuscular Blocker,ASPIRE2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding excessively high tidal volumes during positive pressure ventilation,ASPIRE6,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Avoiding myocardial Injury,ASPIRE18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoiding acute kidney injury,ASPIRE19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Breast Reconstruction: Return to OR,ASPS5,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Breast Reconstruction: Flap Loss,ASPS6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Blood Transfusion for Patients Undergoing Autologous Breast Reconstruction,ASPS7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Coordination of Care for Patients Undergoing Breast Reconstruction,ASPS8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Length of Stay Following Autologous Breast Reconstruction,ASPS9,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction with Information Provided during Breast Reconstruction,ASPS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Operative Time for Autologous Breast Reconstruction,ASPS11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned hospital admission after panniculectomy,ASPS12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Wound disruption rate after primary panniculectomy in patients with BMI > or = to 35,ASPS13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Wound disruption rate after primary panniculectomy in patients with BMI < 35,ASPS14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Seroma rate after primary panniculectomy,ASPS15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Complete assessment and evaluation of patient's pelvic organ prolapse prior to surgical repair,AUGS1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative assessment of sexual function prior to pelvic organ prolapse repair,AUGS3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing an intraoperative rectal examination at the time of prolapse repair,AUGS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing vaginal apical suspension at the time of hysterectomy to address pelvic organ prolapse,AUGS5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Route of Hysterectomy,AUGS6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation that conservative management was offered prior to fecal incontinence surgery or procedures,AUGS7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of weight loss counseling prior to surgery for stress urinary incontinence procedures for obese women,AUGS8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Over-utilization of synthetic mesh in the posterior compartment,AUGS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of offering a preoperative pessary for Pelvic Organ Prolapse,AUGS10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation that a trial of conservative management was offered prior to use of procedure based therapy for urgency urinary incontinence,AUGS11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Comprehensive Assessment of Safety,BIVARUS27,Registry/QCDR,Patient Engagement/Experience,N,--,--,--,--,--,--,--,--,--
Patient Reported Experience and Care Coordination,BIVARUS28,Registry/QCDR,Patient Engagement/Experience,N,--,--,--,--,--,--,--,--,--
Patient Reported Care Team Communication,BIVARUS32,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Patient Reported Procedure Readiness and Care,BIVARUS33,Registry/QCDR,Patient Engagement/Experience,N,--,--,--,--,--,--,--,--,--
Turn-Around Time (TAT) - Standard biopsies,CAP1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma and Carcinosarcoma of the Endometrium,CAP2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Invasive Carcinoma of Renal Tubular Origin,CAP3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma of the Intrahepatic Bile Ducts Completed,CAP4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Hepatocellular Carcinoma Completed,CAP5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma of the Pancreas Completed,CAP6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Helicobacter pylori documentation rate,CAP7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Turn-Around Time (TAT) - Lactate,CAP8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Turn-Around Time (TAT) - Troponin,CAP9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Knee Arthroplasty,CCOME1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Hip Arthroplasty,CCOME2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Shoulder Arthroplasty,CCOME3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after ACLR Surgery,CCOME4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Extent of Osteoarthritis Observed in Arthroscopic Partial Meniscectomy,CCOME5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after APM Surgery,CCOME6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adequate Off-loading of Diabetic Foot Ulcers at each visit,CDR1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Foot Ulcer (DFU) Healing or Closure,CDR2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Plan of Care Creation for Diabetic Foot Ulcer (DFU) Patients not Achieving 30% Closure at 4 Weeks AND Plan of Care Creation for Venous Leg Ulcer (VLU) Patients not Achieving 30% Closure at 4 Weeks,CDR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adequate Compression at each visit for Patients with Venous Leg Ulcers (VLU),CDR5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Venous Leg Ulcer outcome measure: Healing or Closure,CDR6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Use of hyperbaric oxygen therapy for patients with diabetic foot ulcers,CDR8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate use of Cellular or Tissue Based Products (CTP) for patients aged 18 years or older with a diabetic foot ulcer (DFU) or venous leg ulcer (VLU),CDR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post operative hypocalcemia after thyroidectomy surgery,CESQIP1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Related readmission for thyroid or parathyroid related problems,CESQIP2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Pre operative ultrasound exam of patients with thyroid cancer,CESQIP3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Persistent hypercalcemia,CESQIP4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Related readmission for adrenal related problems,CESQIP5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Vocal cord dysfunction following thyroidectomy,CESQIP7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hematoma requiring evacuation following thyroidectomy,CESQIP8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Back Pain: Use of EMG & CNS,CLLC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Morton's Neuroma - Avoidance of Alcohol Injections,CLLC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Patients - Survivorship Care Plan,CLLC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Foot Bone Infection Diagnosis Without MRI,CLLC4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Shoulder Replacement,CODE1,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for ACL Repair,CODE2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Foot/Ankle Repair,CODE3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Spine Surgery,CODE5,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Hip Replacement,CODE6,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Knee Replacement,CODE7,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Cervical Surgery,CODE8,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Hand/Wrist/Elbow Repair,CODE9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Shoulder Arthroscopy,CODE10,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Knee Arthroscopy,CODE11,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Hip Arthroscopy,CODE12,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"CAHPS Clinician/Group Surveys - (Adult Primary Care, Pediatric Care, and Specialist Care Surveys)",CUHSM3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
CAHPS Health Plan Survey v 4.0 - Adult questionnaire,CUHSM4,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder,CUHSM6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiovascular Health Screening for People With Schizophrenia or Bipolar Disorder Who Are Prescribed Antipsychotic Medications,CUHSM8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneEGFR,CURE1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneALK,CURE2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneROS1,CURE3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneNSCLCBRAF,CURE4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOnePDL1,CURE5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneMelBRAF,CURE6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneEGFRTTP,CURE7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneALKTTP,CURE8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneROS1TTP,CURE9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneNSCLCBRAFTTP,CURE10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneMelBRAFTTP,CURE11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Door to Diagnostic Evaluation by a Provider ?Adult Emergency Department (ED) Patients,ECPR2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Lower Acuity ED Patients,ECPR5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Higher Acuity ED Patients,ECPR6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,Registry/QCDR,Process,Y,65.22 - 73.99,74.00 - 77.49,77.50 - 80.64,80.65 - 84.37,84.38 - 86.46,86.47 - 89.28,89.29 - 92.76,>= 92.77,No
Pain Management for Long Bone Fracture,ECPR40,Registry/QCDR,Process,Y,91.67 - 92.97,92.98 - 93.74,93.75 - 95.44,95.45 - 96.42,96.43 - 97.95,97.96 - 99.99,--,100,Yes
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ECPR41,Registry/QCDR,Process,Y,55.22 - 67.88,67.89 - 74.73,74.74 - 84.81,84.82 - 86.89,86.90 - 90.57,90.58 - 98.27,98.28 - 99.04,>= 99.05,No
Restrictive Use of Blood Transfusions,ECPR42,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Creatine Kinase-MB (CK-MB) Testing for Non-traumatic Chest Pain,ECPR45,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Opiate Prescriptions for Low Back Pain or Migraines,ECPR46,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain,ECPR47,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions,ECPR48,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Tramadol or Codeine for Children,ECPR49,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Door to Diagnostic Evaluation by a Provider Within 30 Minutes - Urgent Care Patients,ECPR50,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Short-term Pain Management/Maximum Pain Score,EPREOP4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preoperative Frailty Assessment,EPREOP28,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative Assessment for Opioid Dependence Risk,EPREOP29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Review of Functional Status Assessment for Patients with Osteoarthritis,FORCE20,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Review of Pain Status Assessment for Patients with Osteoarthritis,FORCE21,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improvement in Pain after Knee Replacement,FORCE22,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improvement in Pain after Hip Replacement,FORCE23,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate management of anticoagulation in the peri-procedural period rate ?EGD,GIQIC10,Registry/QCDR,Process,Y,74.07 - 83.50,83.51 - 89.65,89.66 - 96.61,96.62 - 97.84,97.85 - 99.99,--,--,100,Yes
Appropriate indication for colonoscopy,GIQIC12,Registry/QCDR,Process,Y,84.85 - 87.69,87.70 - 90.11,90.12 - 92.09,92.10 - 93.79,93.80 - 95.58,95.59 - 96.90,96.91 - 98.74,>= 98.75,No
Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients,GIQIC15,Registry/QCDR,Process,Y,68.00 - 75.99,76.00 - 82.34,82.35 - 85.03,85.04 - 87.87,87.88 - 90.62,90.63 - 92.30,92.31 - 95.34,>= 95.35,No
Appropriate follow-up interval of 5 years for colonoscopies with findings of sessile serrated polyps < 10 mm without dysplasia,GIQIC17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm,GIQIC18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate indication for esophagogastroduodenoscopy (EGD),GIQIC19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate follow-up interval of 10 years for colonoscopies with only hyperplastic polyp findings,GIQIC20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HAdv1 - Use of high risk sleep medications in the elderly,HADV1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HAdv2 - Atrial Fibrillation Prevention and Treatment - Lifestyle and Disease Factor Assessment,HADV2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Mean Length of Stay for Inpatients - Pneumonia,HCPR3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Length of Stay for Inpatients - CHF,HCPR4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Length of Stay for Inpatients - COPD,HCPR5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stroke Venous Thromboembolism (VTE) Prophylaxis,HCPR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Venous Thromboembolism (VTE) Prophylaxis,HCPR14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Physician's Orders for Life-Sustaining Treatment (POLST) Form,HCPR16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pressure Ulcers - Risk Assessment and Plan of Care,HCPR17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unintentional Weight Loss - Risk Assessment and Plan of Care,HCPR18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
30 Day All-Cause Readmission Rate for Discharged Inpatients,HCPR19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Clostridium Difficile - Risk Assessment and Plan of Care,HCPR20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Use of Telemetry for Admission or Observation Placement,HCPR21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Care Transfer of Care - Use of Verbal Checklist or Protocol,HCPR22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Exclusive Breast Milk Feeding,HEF1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Surgical Reconstruction for Anterior Cruciate Ligament (ACL) Injury,HF2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Shoulder Instability - Labral Reconstruction: Change in Validated Shoulder Patient Reported Outcome Measure Following Labral Reconstruction for Shoulder,HF3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Shoulder Arthroscopy: Measure of Change in a Validated Shoulder Patient Reported Outcome Following Shoulder Arthroscopy,HF4,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Shoulder Arthroplasty: Change in a Validated Shoulder Patient Reported Outcome Measure Following Shoulder Arthroplasty,HF5,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Knee Arthroscopy for Meniscal Repair: Change in a Validated Knee Patient Reported Outcome Measure Following Knee Arthroscopy for Meniscal Repair,HF6,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Repair for Rotator Cuff Tear: Change in a Validated Shoulder Patient Reported Outcome Measure Following Surgical Rotator Cuff Repair,HF7,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
ACE/ARB use,HM1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
A1C treatment,HM2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
A1C in good control,HM3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Hypogonadism: Serum T, CBC, PSA, IPSS within 6  months of Rx",IQSS1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Prostate Cancer: Newly diagnosed with document T, PSA, Gleason and Prostate Cancer: Initial Eval. Document T, PSA, Gleason",IQSS2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Treatment Options Counseling,IQSS3,Registry/QCDR,Patient Engagement/Experience,N,--,--,--,--,--,--,--,--,--
BPH: Anticholinergics,IQSS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Counseling SUI,IQSS5,Registry/QCDR,Patient Engagement/Experience,N,--,--,--,--,--,--,--,--,--
Corneal Graft Surgery - Postoperative Improvement in Visual Acuity of 20/40 or greater,IRIS1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma - Intraocular Pressure (IOP)Reduction,IRIS2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma - Visual Field Progression,IRIS3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma - Intraocular Pressure Reduction Following Laser Trabeculoplasty,IRIS4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgery for Acquired Involutional Ptosis - Patients with an Improvement of Marginal Reflex Distance,IRIS5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acquired Involutional Entropion - Normalized Lid Position After Surgical Repair,IRIS6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amblyopia - Interocular Visual Acuity,IRIS7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Esotropia: Postoperative Alignment,IRIS8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Retinopathy - Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy,IRIS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Exudative Age-Related Macular Degeneration - Loss of Visual Acuity,IRIS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Nonexudative Age-Related Macular Degeneration - Loss of Visual Acuity,IRIS11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Macular Edema: Loss of Visual Acuity,IRIS13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acute Anterior Uveitis: Post-treatment visual acuity,IRIS16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells,IRIS17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Chronic Anterior Uveitis: Post-treatment visual acuity,IRIS18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Idiopathic Intracranial Hypertension: No worsening or improvement of mean deviation,IRIS20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ocular Myasthenia Gravis: Improvement of ocular deviation or absence of diplopia or functional improvement,IRIS21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Giant Cell Arteritis: Absence of fellow eye involvement after corticosteroid treatment,IRIS22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Refractive Surgery: Postoperative Improvement in Uncorrected Visual Acuity of 20/20 or better,IRIS23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Refractive Surgery:  Postoperative correction within + 0.5 Diopter of the Intended Correction,IRIS24,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adenoviral Conjunctivitis:  Avoidance of Antibiotics,IRIS25,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Intravitreal Injections: Avoidance of Routine Antibiotic Use,IRIS26,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Adverse Events After Cataract Surgery,IRIS27,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Regaining Vision After Cataract Surgery,IRIS28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved visual acuity after epiretinal membrane treatment within 90 days,IRIS29,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Return to OR within 90 days after epiretinal membrane surgical treatment,IRIS30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoidance of Genetic Testing for Age-related Macular Degeneration,IRIS31,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Evidence of anatomic closure of macular hole within 90 days after surgery as documented by OCT.,IRIS32,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Return to OR within 90 days after macular hole surgery,IRIS33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Age-Related Macular Degeneration: Disease Progression,IRIS34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Functional Improvement in hip, leg or ankle rehabilitation in patients with lower extremity injury measured via the validated Lower Extremity Function Scale (LEFS) score.",IROMS1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Improvement in knee rehabilitation of patients with knee injury measured via their validated Knee Outcome Survey (KOS) score.,IROMS2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Functional Improvement in arm, shoulder, and hand rehabilitation in surgical patients with musculotendinous injury measured via the validated Disability of Arm Shoulder and Hand (DASH) score.",IROMS8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Improvement in neck pain/injury patients rehabilitation measured via the validated Neck Disability Index (NDI).,IROMS9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Improvement in low back rehabilitation of non-surgical patients with low pack pain measured via the validated Modified Low Back Pain Disability Questionnaire (MDQ).,IROMS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Procedures with statin and antiplatelet agents prescribed at discharge,M2S1,Registry/QCDR,Process,Y,66.13 - 67.64,67.65 - 69.04,69.05 - 75.12,75.13 - 78.78,78.79 - 83.32,83.33 - 87.65,87.66 - 93.74,>= 93.75,No
Amputation-free survival assessed at least 9 months following Infra Inguinal Bypass for intermittent claudication,M2S2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amputation-free survival assessed at least 9 months following Peripheral Vascular Intervention for intermittent claudication,M2S5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ipsilateral stroke-free survival assessed at least 9 months following Carotid Artery Stenting for asymptomatic procedures,M2S7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ipsilateral stroke-free survival assessed at least 9 months following isolated CEA for asymptomatic procedures,M2S8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Imaging-based maximum aortic diameter assessed at least 9 months following Thoracic and Complex EVAR procedures,M2S9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Survival at least 9 months after elective repair of small thoracic aortic aneurysms,M2S10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Imaging-based maximum aortic diameter assessed at least 9 months following Endovascular AAA Repair procedures,M2S11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Survival at least 9 months after elective repair of small abdominal aortic aneurysms,M2S12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Survival at least 9 months after elective open repair of small abdominal aortic aneurysms,M2S13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Absence of unplanned reoperation after closed lower extremity major amputation,M2S16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 17: Absence of serious technical complications during peripheral arterial intervention,M2S17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 19: Proper patient selection for perforator vein ablation,M2S19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Case Delay,MA1,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Corneal Abrasion,MA3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Anxiety Utilization of the GAD-7 Tool,MBHR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Anxiety Response at 6-months,MBHR2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion within 30 days following primary LRYGB or LSG operation.",MBSAQIP7,Registry/QCDR,Outcome,Y,2.04 -  1.86,1.85 -  1.85,1.84 -  1.49,1.48 -  0.01,--,--,--,0,Yes
Risk standardized rate of patients who experienced extended length of stay (> 7 days) following primary LRYGB or LSG operation,MBSAQIP8,Registry/QCDR,Outcome,Y,0.31 -  0.01,--,--,--,--,--,--,0,Yes
Risk standardized rate of patients who experienced a postoperative escalation in care event following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP10,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Risk standardized rate of patients who experienced a pulmonary complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy,MBSAQIP11,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Risk standardized rate of patients who experienced a postoperative complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP12,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
"Use of a ""PEG Test"" to Manage Patients Receiving Opioids",MEDNAX52,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX1: Heel Pain Treatment Outcomes for Adults,MEX1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2: Heel Pain Treatment Outcomes for Pediatric Patients,MEX2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX3: Identification of Flat Foot in Pediatric Patients,MEX3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX2018-2: Bunion Outcome - Adult and Adolescent,MEX4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-3: Hammer Toe Outcome,MEX5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-11: Peripheral Vascular Assessment - Patients 70+,MEX6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX2018-6: Foot Wound Outcome,MEX7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-20: Non-Invasive Vascular Testing Follow-up in Patients After Revascularization,MEX8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-16: Non-Invasive Vascular Testing in Patients Diagnosed with Intermittent Claudication Who Use Cilostazol or Pentoxifylline,MEX9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Vascular Testing Outcome Measure Supervised Programs,MEX10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-19: Non-Invasive Vascular Testing in Patients with Abnormal CVI Screening That Completed Hyperbaric Oxygen Therapy,MEX11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peripheral Vascular Assessment % of Diabetic Patients 50+,MEX12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX2018-22: Patients with Lower Limb Ulceration with a Previously Abnormal Vascular Study Receiving Negative Pressure Wound Therapy,MEX13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Plan All Cause Readmissions,MHAN3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
General Health Postoperative Improvement,MICS1,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Surgery Specific Postoperative Improvement in Pain Levels,MICS2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Surgery Specific Postoperative Improvement in Function Levels,MICS3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Perioperative Pain Plan,MIRAMED16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of witnessed gastric aspiration,MIRAMED17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Conversion to General Anesthesia from Regional or MAC for all scheduled cases,MIRAMED18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Onset atrial fibrillation or dysrthymia requiring unanticipated therapy,MIRAMED19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Perioperative cognitive function test in elderly,MIRAMED20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ischemic Vascular Disease Use of Aspirin or Anti-platelet Medication,MNCM5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes A1c Control (<8.0),MNCM6,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Objectifying pain and/or functionality to determine manipulative medicine efficacy with correlative treatment adjustment,MOA1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Use of Advanced Imaging by Ordering Provider,MOA2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adherence to Controlled Substance Agreement/Opiate Agreement with Corrective Actions for Violations,MOA7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Efficacy of Manipulative Medicine with Treatment Adjustment,MOA12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Urine Drug Screen Utilization in Pain Management and Substance Use Disorders; no less than quarterly for pain and no less than monthly for substance use disorders,MOA13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Addressing anxiety in pain patients with SNRI and SSRIs and reducing/eliminating benzodiazepines for chronic anxiety,MOA14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Weight loss in pain patients with BMI > = 30 with opiate utilization for weight related pain conditions rather than opiate dose escalation for improved pain control,MOA15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Pre-surgical screening for depression,MSSIC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent same-day ambulation,MSSIC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of use of Pre-op skin preparation/wash,MSSIC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for back or neck pain,MSSIC8,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for leg or arm pain,MSSIC9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for pain-related disability (ODI/NDI),MSSIC10,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Percent Satisfied with Result,MSSIC11,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of hospital readmission,MSSIC12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of surgical site infection,MSSIC13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of urinary retention,MSSIC14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for myelopathy,MSSIC16,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy,MUSIC1,Registry/QCDR,Process,Y,98.57 - 98.95,98.96 - 99.99,--,--,--,--,--,100,Yes
Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients:,MUSIC3,Registry/QCDR,Process,Y,47.51 - 50.40,50.41 - 52.25,52.26 - 55.92,55.93 - 56.83,56.84 - 60.46,60.47 - 62.28,62.29 - 68.41,>= 68.42,No
Prostate Cancer: Proportion of patients with low-risk prostate cancer receiving active surveillance,MUSIC4,Registry/QCDR,Process,Y,9.52 - 11.85,11.86 - 13.72,13.73 - 15.89,15.90 - 17.85,17.86 - 21.56,21.57 - 27.37,27.38 - 33.32,>= 33.33,No
Prostate Cancer: Percentage of prostate cancer cases with a length of stay > 2 days,MUSIC5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Biopsy: Proportion of patients undergoing a repeat prostate biopsy within 12 months of their initial biopsy in the registry as a result of a finding of atypical small acinar proliferation (ASAP) as per the NCCN guidelines,MUSIC9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Confirmation Testing in low risk AS eligible patients,MUSIC10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Follow-Up.Testing for patients on.active surveillance for at.least 30 months,MUSIC11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Alcohol Problem Use Assessment for Home-Based Primary Care and Palliative Care Patients,NHBPC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screen for Risk of Future Fall for Home-Based Primary Care and Palliative Care Patients,NHBPC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Delirium Assessment in Home-Based Primary Care and Palliative Care Patients: Medication List Reviewed & Offending Medications Discontinued (Multiperformance-Rate Measure),NHBPC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Referral to Hospice for Appropriate Home-Based Primary Care and Palliative Care Patients,NHBPC9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Telephone Contact, Virtual, or In-person Visit Within 48 Hours of Hospital Discharge of Home-Based Primary Care and Palliative Care Patients",NHBPC10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Interdisciplinary Team Assessment for Home-Based Primary care and Palliative Care Patients,NHBPC13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cognitive Assessment for Home-Based Primary Care and Palliative Care Patients,NHBPC14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
A Functional Assessment (Basic and Instrumental Activities of Daily Living [ADL]) for Home-Based Primary Care and Palliative Care Patients (Multiperformance Measure),NHBPC15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Outcome for Home-Based Primary Care and Palliative Care Practices,NHBPC16,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Screening for Depression and Follow-up Plan in Home-Based Primary Care and Palliative Care Patients,NHBPC17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Repeat colonoscopy recommended due to poor bowel preparation,NHCR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Repeat colonoscopy recommended due to piecemeal resection,NHCR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate indication for colonoscopy,NHCR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
APPROPRIATE PATIENT SELECTION FOR DIAGNOSTIC FACET JOINT PROCEDURES,NIPM4,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
AVOIDING EXCESSIVE USE OF EPIDURAL INJECTIONS IN MANAGING CHRONIC PAIN ORIGINATING IN THE CERVICAL AND THORACIC SPINE,NIPM8,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
AVOIDING EXCESSIVE USE OF THERAPEUTIC FACET JOINT INTERVENTIONS IN MANAGING CHRONIC CERVICAL AND THORACIC SPINAL PAIN,NIPM9,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
COMMUNICATING CONCURRENT OPIOID AND BENZODIAZEPINE PRESCRIBING TO OTHER PRESCRIBERS,NIPM10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
PATIENT COUNSELING REGARDING RISKS OF CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES,NIPM11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
FUNCTIONAL STATUS ASSESSMENT FOR SPINAL CORD STIMULATOR IMPLANTATION,NIPM12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
FUNCTIONAL STATUS ASSESSMENT FOR LUMBAR MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
FUNCTIONAL STATUS ASSESSMENT FOR CERVICAL MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
REDUCTION IN PATIENT REPORTED PAIN FOLLOWING SPINAL CORD STIMULATOR IMPLANTATION FOR FAILED BACK SURGERY SYNDROME,NIPM15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
REDUCTION IN PATIENT REPORTED PAIN FOLLOWING LUMBAR MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
REDUCTION IN PATIENT REPORTED PAIN FOLLOWING CERVICAL/THORACIC MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical Result: Pulmonary Embolism,NJIISMD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: ICH,NJIISMD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Aortic Dissection,NJIISMD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Occlusive intracranial stroke,NJIISMD8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Placental abruption,NJIISMD9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Ruptured ectopic pregnancy,NJIISMD10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: New DVT,NJIISMD11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Eptopic Pregnancy,NJIISMD12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Result Requiring Follow Up Protocol,NJIISMD17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Cord Compression,NJIISMD19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: CTA of GI bleed,NJIISMD20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Positive bleeding scan,NJIISMD21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Acute Ocular injury,NJIISMD22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Substance Use Screening,NNEPTN1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transforming Clinical Practice Initiative Common Measure Name: Substance Use Screening and Intervention Composite,NNEPTN2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transforming Clinical Practice Initiative Common Measure Name: TCP01: Documentation of a Comprehensive Health and Life Plan Developed Collaboratively by the Patient and the Health Professional Team,NNEPTN3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hip Fracture Mortality Rate (IQI 19),NOF6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Osteoporosis: percentage of patients, any age, with a diagnosis of osteoporosis who are either receiving both calcium & vitamin D intake, & exercise at least once within 12 months.",NOF7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Median Time to Pain Management for Long Bone Fracture,NOF12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older",NOF13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Functional Outcome Assessment for Spine Intervention,NPA3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality-of-Life Assessment for Spine Intervention,NPA4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction with Spine Care,NPA5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Spine-related procedure site infection,NPA6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Readmission Following Spine Procedure Within the 30 Day Post-Operative Period,NPA11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Selection of Prophylactic Antibiotic Prior to Spine Procedure,NPA12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medicine Reconciliation Following Spine Related Procedure,NPA14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Risk Assessment for Elective Spine Procedure,NPA15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Depression and Anxiety Assessment Prior to Spine-Related Therapies,NPA16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Narcotic Pain Medicine Management Following Elective Spine Procedure,NPA17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Smoking Assessment and Cessation Coincident With Spine-Related Therapies,NPA18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Body Mass Assessment and Follow-up Coincident With Spine-Related Therapies,NPA19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unhealthy Alcohol Use Assessment Coincident With Spine Care,NPA20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Spine/Extremity Pain Assessment,NPA23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Outcome Assessment for Spine Intervention,NPAGSC3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality-of-Life Assessment for Spine Intervention,NPAGSC4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction with Spine Care,NPAGSC5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Depression and Anxiety Assessment Prior to Spine-Related Therapies,NPAGSC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Narcotic Pain Medicine Management Prior to and Following Spine Therapy,NPAGSC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Complication Following Percutaneous Spine-Related Procedure,NPAGSC8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Admission to Hospital Following Percutaneous Spine Procedure within the 30-Day Post-procedure Period,NPAGSC9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Spine/Extremity Pain Assessment,NPAGSC10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Notification to the ordering provider requesting myoglobin or CK-MB in the diagnosis of suspected acute myocardial infarction (AMI).,NPQR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Notification to the ordering provider requesting thyroid screening tests other than only a Thyroid Stimulating Hormone (TSH) test in the initial screening of a patient with a suspected thyroid disorder,NPQR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Notification to the ordering provider requesting amylase testing in the diagnosis of suspected acute pancreatitis,NPQR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for chemistry,NPQR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for cerebrospinal fluid - white blood cell (CSF - WBC),NPQR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for toxicology,NPQR6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for troponin,NPQR7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of review of slides with high-grade squamous intraepithelial lesion (HSIL) with negative cervical biopsies,NPQR8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of follow up letter after high-grade squamous intraepithelial lesion (HSIL) pap test,NPQR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of amended pathology reports with a major discrepancy,NPQR10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of communicating results of an amended report with a major discrepancy to the responsible provider,NPQR11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of cytopathology case review,NPQR12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of notification to clinical provider of a new diagnosis of malignancy,NPQR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Frozen section diagnosis within 20 minutes of receipt in lab (single block frozen section),NPQR14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post Stroke Outcome and Follow-Up,OBERD22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Health Related Quality of Life: Patient Defined Outcomes,OBERD23,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Tracking Satisfaction Improvement with CG-CAHPS,OBERD25,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Cervical Spine Functional Outcomes,OBERD26,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Foot/Ankle Functional Outcomes,OBERD27,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Hip Functional Outcomes,OBERD28,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Knee Functional Outcomes,OBERD29,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Lumbar Spine Functional Outcomes,OBERD30,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life-Mental Health Outcomes,OBERD31,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life - Physical Health Outcomes,OBERD32,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Patient Acceptable Symptom State Outcomes,OBERD33,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Upper Extremity Functional Outcomes,OBERD34,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"Emergent transfer from an outpatient, ambulatory surgical center, or office setting",OEIS2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Antiplatelet Therapy,OEIS3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Lipid-Lowering Medications for Patients with PAD,OEIS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Appropriate non-invasive arterial testing for patients with intermittent claudication who are undergoing a LE peripheral vascular intervention,OEIS6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Goal Setting and Attainment for Cancer Survivors,ONSQIR18,Registry/QCDR,Patient Engagement/Experience,N,--,--,--,--,--,--,--,--,--
Fatigue Improvement,ONSQIR20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Advance Care Planning in Stage 4 Disease,PIMSH1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Utilization of GCSF in Metastatic Colon Cancer,PIMSH2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0 or Stage IB-III hormone receptor negative breast cancer,PIMSH3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
30 day Readmission for Acute Myocardial Infarction,PINC1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
30 day Mortality for Acute Myocardial Infarction,PINC4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Acute Myocardial Infarction (AMI),PINC33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Heart Failure (HF),PINC34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Pneumonia (PN),PINC35,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Annual Monitoring for Patients on Persistent Medications (MPM),PP1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Follow-Up After Hospitalization for Schizophrenia (7- and 30-day),PP2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
ADHD: Symptom Reduction in Follow up Period,PP3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risky Behavior Assessment or Counseling by Age 18 Years,PP4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Bipolar disorder: the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their symptom complex within 12 weeks of initiating treatment; AND if there is no change or deterioration in symptoms, a revised care plan is documented following the 12 week monitoring phase",PP5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pharmacological Treatment of Dementia,PP6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC),PP7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Antiplatelet Medication for High Risk Patients,PPRNET8,Registry/QCDR,Process,Y,27.54 - 34.44,34.45 - 48.69,48.70 - 52.69,52.70 - 58.35,58.36 - 62.68,62.69 - 68.37,68.38 - 72.62,>= 72.63,No
Chronic Kidney Disease (CKD): eGFR Monitoring,PPRNET13,Registry/QCDR,Process,Y,64.27 - 66.85,66.86 - 70.65,70.66 - 73.32,73.33 - 77.17,77.18 - 81.20,81.21 - 84.50,84.51 - 89.99,>= 90.00,No
Chronic Kidney Disease (CKD): Hemoglobin Monitoring,PPRNET14,Registry/QCDR,Process,Y,62.26 - 77.26,77.27 - 79.08,79.09 - 86.62,86.63 - 89.65,89.66 - 90.47,90.48 - 93.47,93.48 - 96.14,>= 96.15,No
Appropriate Treatment for Adults with Upper Respiratory Infection,PPRNET24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
NSAID or Cox 2 Inhibitor Use in Patients with Heart Failure (HF) or Chronic Kidney Disease (CKD),PPRNET28,Registry/QCDR,Process,Y,80.89 - 83.26,83.27 - 85.20,85.21 - 85.70,85.71 - 86.44,86.45 - 87.98,87.99 - 89.31,89.32 - 94.23,>= 94.24,No
Monitoring Serum Potassium,PPRNET29,Registry/QCDR,Process,Y,80.47 - 81.95,81.96 - 83.76,83.77 - 87.74,87.75 - 90.46,90.47 - 92.78,92.79 - 94.58,94.59 - 97.21,>= 97.22,No
Screening for Type 2 Diabetes,PPRNET31,Registry/QCDR,Process,Y,81.19 - 84.51,84.52 - 87.46,87.47 - 90.78,90.79 - 92.76,92.77 - 93.62,93.63 - 95.35,95.36 - 98.07,>= 98.08,No
Screening for albuminuria in patients at risk for CKD (DM and/or HTN),PPRNET32,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding Use of CNS Depressants in Patients on Long-Term Opioids,PPRNET33,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Zoster (Shingles) Vaccination,PPRNET34,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented  (Lower Score - Better)",QOPI5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) to III ER/PR negative breast cancer,QOPI11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
GCSF administered to patients who received chemotherapy for metastatic cancer (Lower Score -Better),QOPI15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Oncology: Treatment Summary Communication - Radiation Oncology,QOPI21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
External Beam Radiotherapy for Bone Metastases,QOPI22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Central Venous Line: ultrasound used for placement,QUANTUM31,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Surgical Case Cancellation,QUANTUM41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CKD 3-5 Patients Seen at the Recommended Frequency Levels,RCOIR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CKD 3-5 Patients with a Urine ACR or Urine PCR Lab Test,RCOIR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CKD 4-5 Patients with Transplant Referral,RCOIR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
ESRD Prevalence of Home Dialysis or Self-Care,RCOIR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Improved Access Site Bleeding,RCOIR7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Post Procedure Bleeding,RCOIR8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Upper Extremity Edema Improvement,RCOIR10,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Optimal End Stage Renal Disease (ESRD) Starts,RCOIR11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy,RPAQIR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adequacy of Volume Management,RPAQIR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Arteriovenous Fistula Rate,RPAQIR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transplant Referral,RPAQIR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Advance Care Planning (Pediatric Kidney Disease),RPAQIR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hospitalization Rate Following Procedures Performed under Procedure Sedation Analgesia,RPAQIR11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Arterial Complication Rate Following Arteriovenous Access Intervention,RPAQIR12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician,RPAQIR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Arteriovenous Graft Thrombectomy Success Rate,RPAQIR14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Arteriovenous Fistulae Thrombectomy Success Rate,RPAQIR15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peritoneal Dialysis Catheter Success Rate,RPAQIR16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peritoneal Dialysis Catheter Exit Site Infection Rate,RPAQIR17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Advance Directives Completed,RPAQIR18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SCG1 Evaluation of High Risk Pain Medications for MME,SCG1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SCG2 Outcome Assessment for Patients Prescribed Ankle Orthosis for Ambulation and Functional Improvement,SCG2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SCG3 Outcome Assessment for Patients Prescribed Foot Orthosis for Ambulation and Functional Improvement,SCG3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prevention of Antibiotic or Herbal Supplement Impairment of Anesthesia,SCG4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Improvement in Quality of Life from Partial Foot, Prosthetics",SCG05,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Outcome of High Risk Pain Medications Prescribed in Last 6 Months,SCG6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Education of patients with inflammatory diseases regarding increased cardiovascular risk and the need for PCP evaluation,SDPAD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HCV testing in Lichen Planus,SDPAD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding antibiotic use in rupture epidermal inclusion cyst,SDPAD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Testing and Treatment of Nail tinea infection,SDPAD4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Urgent Result:  Breast Specimen Radiography,SMD23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result:  Testicular Torsion,SMD24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result:  Subdural hematoma,SMD25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
GI Radiography Result Notification..Critical Result:  Bowel Obstruction..Critical Result:  Sigmoid Volvulus,SMD26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Chest Imaging Result Notification:..Critical Result:  Pneumothorax..Critical Result:  Tension Pneumothorax..Follow Up Result:  Suspicious Lung Nodule,SMD27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Musculoskeletal Radiology Result Notification:..Critical Result:  Fracture C-Spine..Urgent Result: Osteomyelitis..Urgent Result:  Meniscal Tear.,SMD28,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia,SMX1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications,SMX2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SMX1004: Use of Multiple Concurrent Antipsychotics in Children and Adolescents,SMX3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Adherence for Diabetes Medication,SMX5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screening for Psychiatric or Behavioral Health Disorders,SMX6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Adherence for Hypertension,SMX7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment and Intervention for Psychosocial Distress in Adults Receiving Cancer Treatment,SMX8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Mental Health Assessment for Patients with orthopedic conditions,SMX9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Repeated X-Ray Imaging,SPINEIQ3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Change in Functional Outcomes,SPINEIQ5,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Change in Pain Intensity,SPINEIQ6,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
MRI  of the lumbar spine without prior conservative care,SPINEIQ7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting MCID thresholds for back or neck pain,SPINETRACK1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting MCID thresholds for leg or arm pain,SPINETRACK2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting MCID thresholds for pain-related disability (ODI/NDI).,SPINETRACK3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting SCB thresholds for back or neck pain.,SPINETRACK4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting SCB thresholds for leg or arm pain,SPINETRACK5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting SCB thresholds for pain-related disability (ODI/NDI),SPINETRACK6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Assessment and Management of Muscle Spasticity--Inpatient,SQOD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Management of Muscle Spasticity--Outpatient,SQOD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post-Acute Brain Injury: Depression Screening and Follow-Up Plan of Care,SQOD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Family Training-Inpatient Rehabilitation/Skilled Nursing Facility-Discharged to Home,SQOD4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Assessment to Determine Rehabilitation Needs,SQOD5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prolonged Length of Stay following CABG,STS1,Registry/QCDR,Outcome,Y,7.94 -  6.34,6.33 -  5.27,5.26 -  4.40,4.39 -  3.58,3.57 -  2.74,2.73 -  2.01,2.00 -  0.94,<=  0.93,No
Prolonged Length of Stay following CABG and Valve Surgery,STS3,Registry/QCDR,Outcome,Y,15.38 - 14.30,14.29 - 12.51,12.50 - 10.72,10.71 -  8.21,8.20 -  6.68,6.67 -  4.77,4.76 -  3.46,<=  3.45,No
Prolonged Length of Stay following Valve Surgery,STS5,Registry/QCDR,Outcome,Y,9.52 -  7.33,7.32 -  5.57,5.56 -  4.77,4.76 -  4.01,4.00 -  2.64,2.63 -  0.01,--,0,No
Patient Centered Surgical Risk Assessment and Communication using the STS Risk Calculator,STS7,Registry/QCDR,Patient Engagement/Experience,Y,4.46 - 11.69,11.70 - 23.42,23.43 - 43.58,43.59 - 69.90,69.91 - 82.75,82.76 - 89.18,89.19 - 96.68,>= 96.69,No
Operative Mortality for Esophageal Resection,STS8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Recording Performance Status prior to Esophageal Cancer Resection,STS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Operative Mortality for Lobectomy,STS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lobectomy - Air Leak Greater than 5 Days,STS11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lobectomy - Unplanned Return to OR,STS12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Recording Performance Status Prior to Lung Cancer Resection,STS13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
UR002 - Ankylosing Spondylitis: Controlled Disease,UREQA1,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
UR003 - Ankylosing Spondylitis: Appropriate Pharmacologic Therapy,UREQA2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
UR008 - Controlled Gout for Patients on Urate-Lowering Pharmacologic Therapy,UREQA3,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
UR007 - Folic or Folinic Acid Therapy for Patients Treated with Methotrexate,UREQA4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
UR006 - Regular Evaluation of Psoriatic Arthritis (PsA),UREQA5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Vital Sign Assessment Prior to HBOT,USWR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Major Amputation in Wagner 3, 4, or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT.",USWR16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Nutritional Screening and Intervention Plan in Patients with Chronic Wounds and Ulcers,USWR20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Nutritional Assessment in Patients with Wounds and Ulcers,USWR22,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential,USWR23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Reported Experience of Care: Wound Outcome,USWR24,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"Advance Care planning: Electronic submission of new POLST/MOLST/POST/MOST (""orders for life-sustaining treatment"" or ""orders for scope of treatment"") into an eRegistry powered by Medcordance",VCMAHEMR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Care All or None Process Measure: Optimal Testing,WCHQ9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Care All or None Outcome Measure: Optimal Control,WCHQ10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening For Osteoporosis,WCHQ15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Controlling High Blood Pressure: eGFR Test Annually,WCHQ32,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
All-cause Hospital Readmission,458,Administrative Claims,Outcome,Y,15.59 - 15.32,15.31 - 15.02,15.01 - 14.78,14.77 - 14.56,14.55 - 14.33,14.32 - 14.02,14.01 - 13.64,<= 13.63,--